anastrozole has been researched along with tamoxifen in 554 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 17 (3.07) | 18.2507 |
| 2000's | 324 (58.48) | 29.6817 |
| 2010's | 177 (31.95) | 24.3611 |
| 2020's | 36 (6.50) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bellavance, E; Luu-The, V; Poirier, D | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bharate, SS; Vishwakarma, RA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Azab, M; Blomqvist, C; Buzdar, A; Eiermann, W; Howell, A; Jonat, W; Jones, SE; Plourde, PV; Vogel, CL; Webster, A; Wolter, JM | 1 |
| Buzdar, AU; Hortobagyi, GN; Plourde, PV | 1 |
| Hannaford, M | 1 |
| Cala, KM; Landrum, DP; Mahendroo, MS; Russell, DW | 1 |
| Buzdar, AU; Roseman, BJ; Singletary, SE | 1 |
| Blamey, RW; Cheung, KL; Ellis, IO; Elston, CW; Nicholson, RI; Pinder, SE; Robertson, JF; Willsher, PC | 1 |
| Buzdar, AU | 9 |
| Brodie, A; Liu, Y; Long, B; Lu, Q; Wang, JP; Yue, W | 1 |
| Brodie, A; Liu, Y; Long, B; Lu, Q; Wang, J; Yue, W | 1 |
| Baum, M; Blackman, GM; Dowsett, M; Howell, A; King, N; Ponzone, R; Tobias, JS; von Euler, M; Welch, H | 1 |
| Hamilton, A; Piccart, M | 1 |
| Benson, S; Cella, D; Fallowfield, LJ; Howell, A; Leaity, SK | 1 |
| Brodie, A; Gimbel, M; Grigoryev, D; Liu, Y; Long, BJ; Lu, Q | 1 |
| Bland, KI; Buzdar, AU | 1 |
| Bland, KI | 1 |
| Bellamy, C; Cameron, DA; Dixon, JM; Leonard, RC; Love, CD; Miller, WR; Renshaw, L | 1 |
| Harvey, HA; Santen, RJ | 1 |
| Fujiwara, K; Hohjoh, T; Ikeda, T; Kawaguchi, M; Kitajima, M; Masamura, S; Matsui, A; Mitsui, Y; Takayama, S; Tokura, H | 1 |
| Bonneterre, J; Koralewski, L; Krzakowski, M; Mauriac, L; Robertson, J; Steinberg, M; Thürlimann, B; Vergote, I; von Euler, M; Webster, A | 1 |
| Bonneterre, J; Koralewski, P; Krzakowski, M; Mauriac, L; Robertson, JF; Steinberg, M; Thürlimann, B; Vergote, I; von Euler, M; Webster, A | 1 |
| Burton, G; Buzdar, A; Harwin, W; Mangalik, A; Nabholtz, JM; Pollak, M; Steinberg, M; von Euler, M; Webster, A | 1 |
| Sonoo, H; Watanabe, T | 1 |
| Baum, M; Thornton, H; Tobias, JS | 1 |
| Cohen, MH; Flamm Honig, S; Hirschfeld, S; Ibrahim, A; Johnson, JR; O'Leary, JJ; Pazdur, R; White, RM; Williams, GA | 1 |
| Mokbel, K | 2 |
| Panasci, LC | 1 |
| Bagley, CM; Rowbotham, RK | 1 |
| Bolton, M; Copur, MS; Ledakis, P; Muhvic, J; Norvell, M | 1 |
| Tonkin, K | 1 |
| Costa, SD; Kaufmann, M | 1 |
| Bergmann, L | 1 |
| Tominaga, T | 1 |
| Cuzick, J; Dowsett, M; Howell, A; Jackson, I | 1 |
| Lønning, PE | 2 |
| Burstein, HJ; Winer, EP | 1 |
| Murray, R | 1 |
| Boeddinghaus, I; Dixon, M; Dowsett, M; Ebbs, S; Gui, G; Harper-Wynne, C; Hills, M; Sacks, N; Salter, J; Smith, I | 1 |
| Bonneterre, J; Buzdar, A; Nabholtz, JM; Robertson, JF; Sahmoud, T; Steinberg, M; Thürlimann, B; von Euler, M; Webster, A | 1 |
| Nabholtz, JM; Reese, DM | 1 |
| Anderson, TJ; Cameron, DA; Dixon, JM; Miller, WR | 1 |
| Sledge, GW | 1 |
| Baum, M | 4 |
| Goss, PE | 1 |
| Nicholls, H | 1 |
| Jones, SE | 1 |
| Benedetto, C; De Nicola, B; Ferraris, F; Genta, F; Piccinno, R; Porpiglia, M; Vicelli, R | 1 |
| Alba, E; Colla, F; Farina, C; Mazzoleni, A; Ragonesi, G | 1 |
| Ravdin, P | 1 |
| Baum, M; Budzar, AU; Cuzick, J; Forbes, J; Houghton, JH; Klijn, JG; Sahmoud, T | 1 |
| Ingle, JN | 5 |
| Köberle, D; Thürlimann, B | 2 |
| Cummings, FJ | 1 |
| Braun, S; Browman, GP; Burstein, HJ; Chlebowski, RT; Cobleigh, MA; Edge, SB; Goldstein, LJ; Gralow, J; Hudis, C; Ingle, JN; Langer, AS; Mamounas, EP; Perotti, J; Powles, TJ; Pritchard, KI; Whelan, TJ; Winer, EP | 1 |
| Albers, N; Freiberg, C; Roth, C; Zappel, H | 1 |
| Bramwell, V; Vandenberg, T; Winquist, E | 1 |
| Bruntsch, U | 1 |
| Beat, T | 1 |
| Howell, A | 2 |
| Faulds, DM; Wellington, K | 1 |
| Gluck, S | 2 |
| Mokbel, K; Singh-Ranger, G | 2 |
| Hakamata, Y; Hozumi, Y; Nagai, H; Ogura, S; Sasanuma, H | 1 |
| Robertson, JF | 1 |
| Jordan, VC | 2 |
| Coleman, RE | 1 |
| Aumiller, J | 3 |
| Martín de Vidales, C; Pérez-Torrubia, A; Zapatero, A | 1 |
| Miyoshi, Y; Noguchi, S; Taguchi, T; Tamaki, Y | 1 |
| Buzdar, A | 1 |
| Brown, P; Wu, K | 1 |
| Dranitsaris, G; Trudeau, M; Verma, S | 1 |
| Casanovas, J; Milla, L; Milla-Santos, A; Pons, M; Portella, J; Puig-Gali, M; Rallo, L; Rodes, E | 1 |
| Dimmer, C; Goodare, H; Page, K | 1 |
| Thornton, H | 1 |
| Höffken, K; Sayer, HG | 1 |
| Bonneterre, J; Buzdar, A; Nabholtz, JM; Robertson, JF; Thürlimann, B | 2 |
| Rose, C | 1 |
| Brodie, AH; Mouridsen, HT | 1 |
| Thomas, R | 1 |
| Cuzick, J | 3 |
| Dixon, JM; Jackson, J; Miller, WR | 1 |
| Carlini, P; Cognetti, F; Colella, E; Di Cosimo, S; Fabi, A; Ferretti, G; Frassoldati, A; Papaldo, P; Romiti, A; Ruggeri, EM; Tomao, S; Tonachella, R | 1 |
| Aapro, MS; Forbes, JF | 1 |
| Carlson, RW; Henderson, IC | 1 |
| Hortobagyi, GN | 1 |
| Gerber, B | 1 |
| Fleming, GF | 1 |
| Baum, M; Buzdar, A; Cuzick, J; Forbes, J; Houghton, J; Howell, A; Sahmoud, T | 1 |
| Baum, M; Buzdar, A; Howell, A | 1 |
| Dixon, JM; Jackson, J; Miller, WR; Renshaw, L | 1 |
| Nabholtz, JM | 2 |
| Fallowfield, L; Howell, T; Jenkins, V; Shilling, V | 1 |
| Davidson, NE; Emens, L; Visvanathan, K | 1 |
| Pritchard, KI | 1 |
| Smith, IE | 1 |
| Brodie, AH; Mouridsen, HT; Rose, C; Smith, IE | 1 |
| Bianco, AR; Clack, G; Coibion, M; Cuzick, J; Duffy, S; Jackson, TL; Lansdown, M; Philips, K; Pollard, S; Wells, M | 1 |
| Buzdar, A; Jones, D; Simons, WR | 1 |
| Goss, PE; Strasser-Weippl, K | 1 |
| Fallowfield, L; Howell, A; Hutton, S; Jenkins, V; Shilling, V | 1 |
| Aihara, T; Morino, H; Munakata, S; Takatsuka, Y | 1 |
| Cheung, KL; Forward, DP; Jackson, L; Robertson, JF | 1 |
| Kammerer, S | 1 |
| Eiermann, W | 1 |
| Domont, J; Khayat, D; Namer, M; Spano, JP | 1 |
| Kawakami, M; Saji, S; Toi, M | 1 |
| Curran, MP; McKeage, K; Plosker, GL | 1 |
| Baron, M; d'Anjou, J; Dessogne, P | 1 |
| Campos, SM | 1 |
| Arora, A; Potter, JF | 1 |
| Chaudri-Ross, HA; Mouridsen, HT | 1 |
| Aebi, S; Ballabeni, P; Goldhirsch, A; Hess, D; Köberle, D; Pagani, O; Perey, L; Rochlitz, C; Senn, I; Thürlimann, B | 1 |
| Clemons, M; Coleman, RE; Verma, S | 1 |
| Sainsbury, R | 1 |
| Aglietta, M; Cirillo, S; Gatti, M; Martincich, L; Montemurro, F; Regge, D; Russo, F | 1 |
| Aebi, S; Baumann, ChK | 1 |
| Cuzick, J; Locker, GY; Sainsbury, JR | 1 |
| Tobias, JS | 2 |
| Boccardo, F | 2 |
| Hillner, BE | 1 |
| Altundag, K; Buzdar, AU; Hortobagyi, G; Morandi, P; Rouzier, R; Theriault, RL | 1 |
| Ameye, L; Carbonez, A; Christiaens, MR; Morales, L; Neven, P; Paridaens, R; Timmerman, D; Van Huffel, S; Van Limbergen, E; Vergote, I | 1 |
| Bianco, AR; Clack, G; Coibion, M; Duffy, S; Jackson, TL; Lansdown, M; Philips, K; Pollard, S; Wells, M | 2 |
| Cella, D; Cuzick, J; Fallowfield, L; Francis, S; Howell, A; Locker, G | 1 |
| Caruggi, M; Colombo, G; Marchetti, M | 1 |
| Hiura, M; Nogawa, T; Oshita, T; Yokoyama, T | 1 |
| Johnston, S; Stebbing, J | 1 |
| Casper, RF; Diamond, MP; Mitwally, MF | 1 |
| Duffy, SR; Taylor, L | 1 |
| Dowsett, M | 1 |
| Buzdar, A; Macahilig, C | 1 |
| de Cremoux, P; Diéras, V; Fourquet, A; Magdelénat, H; Pierga, JY; Poupon, MF; Sigal-Zafrani, B | 1 |
| Harwood, KV | 1 |
| Fentiman, IS | 1 |
| Travis, K | 1 |
| Battaglia, M; Bertaccini, A; Boccardo, F; Comeri, G; Conti, G; Di Tonno, P; Durand, F; Ferraris, V; Galassi, P; Macchiarella, A; Manganelli, A; Martorana, G; Montefiore, F; Muscas, G; Potenzoni, D; Rubagotti, A; Selvaggi, FP; Siragusa, A; Zattoni, F | 1 |
| Gallo, J; Morris, T; Saltzstein, D; Sieber, P | 1 |
| Beex, L; Come, SE; Jones, SE; Kaufmann, M; Makris, A; Nortier, JW; Possinger, K; Robertson, JF; Rutqvist, LE | 1 |
| Ashley, S; Boeddinghaus, I; Detre, S; Dixon, JM; Dowsett, M; Ebbs, SR; Francis, S; Griffith, C; Hills, M; Salter, J; Skene, A; Smith, IE; Walsh, G | 2 |
| Clemons, MJ; Freedman, OC; Verma, S | 1 |
| Miller, DS; Rao, GG | 1 |
| Michaud, LB | 1 |
| Bershtein, LM; Kovalevskii, AY; Poroshina, TE; Semiglazov, VF; Tsyrlina, EV; Zhil'tsova, EK; Zimarina, TS | 1 |
| Ayaori, M; Hiraide, H; Kusuhara, M; Mochizuki, H; Ohsuzu, F; Sato, K; Sawada, S; Tamaki, K; Yonemura, A | 1 |
| Angeles Victoria, L; Basavilvazo Rodríguez, MA; Castelazo Rico, G; Hernández Valencia, M; Molotla Xolalpa, D; Zárate, A | 1 |
| Jakesz, R | 1 |
| Chen, S; Itoh, T; Karlsberg, K; Kijima, I; Smith, D; Ye, J; Yuan, YC | 1 |
| Boccardo, F; Conti, G; Del Monaco, D; Manganelli, A; Potenzoni, D; Rubagotti, A | 1 |
| Jones, SE; Pippen, J | 1 |
| Brown, P; Kalidas, M | 1 |
| Dodwell, D; Vergote, I | 1 |
| Ingle, JN; Suman, VJ | 1 |
| Ponzone, R; Sismondi, P | 1 |
| Hamilton, AL; Nordman, IC; Spillane, AJ | 1 |
| Ashley, SE; Blohmer, JU; Boeddinghaus, I; Dixon, JM; Dowsett, M; Ebbs, SR; Francis, S; Skene, A; Smith, IE; Walsh, G | 1 |
| Anderson, TJ; Dixon, JM; Evans, D; Krause, A; Larionov, A; Miller, WR; Murray, J; White, S | 1 |
| Amadori, D; Amoroso, D; Benedetto, C; Boccardo, F; Buzzi, F; Distante, V; Fini, A; Franchi, R; Guglielmini, P; Massidda, B; Mesiti, M; Paladini, G; Porpiglia, M; Puntoni, M; Restuccia, N; Rinaldini, M; Romeo, D; Rubagotti, A; Scali, S; Sismondi, P | 1 |
| Banerjee, S; Barker, P; Dowsett, M; Folkerd, L; Iqbal, J; Smith, IE | 1 |
| Gradishar, WJ | 2 |
| Kopans, DB; Ryan, PD; Sgroi, DC | 1 |
| Thönnessen, D; Wenz, F | 1 |
| Glassman, R; Stebbing, J | 1 |
| Dickler, M | 1 |
| Esteva, FJ; Hortobagyi, GN | 1 |
| Attilakos, G; Fox, R | 1 |
| Baum, M; Cuzick, J; Dowsett, M; Houghton, J; Howell, T; Wale, C | 1 |
| Abram, P; Vergote, I | 1 |
| Chen, S; Itoh, T; Kijima, I | 1 |
| Howell, A; Locker, GY | 1 |
| Denes, AE | 1 |
| Demonty, G | 1 |
| Sereda, D; Werth, VP | 1 |
| A'Hern, R; Ashley, S; Boeddinghaus, I; Detre, S; Dixon, JM; Dowsett, M; Ebbs, SR; Francis, S; Griffith, C; Hills, M; Salter, J; Skene, A; Smith, IE; Walsh, G | 1 |
| Buzdar, AU; Cuzick, J | 1 |
| Gerber, B; Janni, W; Krause, A; Kundt, G; Makovitzky, J; Mylonas, I; Reimer, T | 1 |
| Gltick, S | 1 |
| Abrial, C; Cabrespine, A; Chollet, P; Cure, H; Durando, X; Ferriere, JP; Kwiatkowski, F; Leheurteur, M; Mouret-Reynier, MA; Penault-Llorca, F | 1 |
| Rocchi, A; Verma, S | 1 |
| Bines, J; Buzdar, AU; Cataliotti, L; de Oliveira, CT; Dube, P; Noguchi, S; Petrakova, K; Takatsuka, Y | 1 |
| Langenegger, T; Schiesser, D; Thürlimann, B; Wahl, P | 1 |
| Grana, G | 1 |
| Dowsett, M; Hayes, D; Lønning, PE; Santen, RJ; Smith, IE; Walsh, G; Yap, YS | 1 |
| Canorea, F; Del Castillo, A; Gil, JM; González, P; Rubio-Terrés, C | 1 |
| Amadori, D; Benedetto, C; Boccardo, F; Buzzi, F; Distante, V; Fini, A; Franchi, R; Guglielmini, P; Massidda, B; Mesiti, M; Paladini, G; Porpiglia, M; Restuccia, N; Rinaldini, M; Rubagotti, A; Scali, S; Sismondi, P | 1 |
| Duffy, MJ | 1 |
| Brown, MM; Manquez, ME; Shields, CL; Shields, JA | 1 |
| Buzdar, AU; Cuzick, J; Guastalla, JP; Nabholtz, JM | 1 |
| Adams, JE; Clack, G; Cuzick, J; Dowsett, M; Eastell, R; Hannon, RA | 1 |
| Buzdar, A; Cuzick, J; Distler, W; Hoctin-Boes, G; Houghton, J; Howell, A; Locker, GY; Nabholtz, JM; Wale, C | 1 |
| Dewar, R; Rayson, D; Skedgel, C; Younis, T | 3 |
| Borstnar, S; Cufer, T; Mrhar, A; Piskur, P; Sonc, M | 1 |
| Dodwell, D; Pippen, J | 1 |
| Barker, P; Cella, D; Cuzick, J; Fallowfield, L; Howell, A; Locker, G | 1 |
| Annemans, L; Moeremans, K | 1 |
| DiLeonardo, M; Gibbons, G; Resnik, KS | 1 |
| Boccardo, F; Gnant, M; Greenwood, M; Jakesz, R; Jonat, W; Kaufmann, M; Rubagotti, A; Zuna, I | 1 |
| Galid, A; Gnant, MF; Grampp, S; Hausmaninger, H; Jakesz, R; Kaessmann, H; Luschin-Ebengreuth, G; Menzel, C; Mittlboeck, M; Mlineritsch, B; Piswanger-Soelkner, JC; Schmid, M | 1 |
| Chu, QD; Li, BD; McDonald, JC | 1 |
| Kaya, U; Kuscu, E; Oktem, M; Ozen, O; Zeyneloglu, HB | 1 |
| Inoue, K; Nagamoto, N; Ohsako, T; Tanaka, E; Yoshida, Y | 1 |
| A'Hern, R; Detre, S; Dixon, JM; Dowsett, M; Ebbs, SR; Hills, M; Salter, J; Skene, A; Smith, IE; Walsh, G | 1 |
| Lewis, S | 1 |
| Imai, H; Kuroi, K; Ohsumi, S; Ono, M; Shimozuma, K | 1 |
| Cella, D; Dobrez, D; Gandhi, SK; Locker, GY; Mansel, R; Sorensen, S | 1 |
| Ellis, MJ; Rigden, CE | 1 |
| Eisner, A; Falardeau, J; Samples, JR; Toomey, MD; Vetto, JT | 1 |
| Cianfrocca, M; Wolff, AC | 1 |
| Nortier, JW; Seynaeve, C; van de Velde, CJ; van Nes, JG | 1 |
| Draxler, W; Gnant, M; Haider, K; Hammer, J; Handl-Zeller, L; Hofbauer, F; Jakesz, R; Kapp, K; Kwasny, W; Luschin-Ebengreuth, G; Pakisch, B; Pöstlberger, S; Pötter, R; Reiner, G; Rottenfusser, A; Schmid, M; Sedlmayer, F; Stierer, M; Taucher, S; Tausch, C | 1 |
| Akashi-Tanaka, S; Ando, M; Fujiwara, Y; Fukutomi, T; Hasegawa, T; Kinoshita, T; Omatsu, M; Seki, K; Shien, T; Shimizu, C; Terada, K | 1 |
| Lian, ZQ; Yang, MT | 1 |
| Aapro, M; Cannon, H; Georgiou, V; Leto di Priolo, S; Wengström, Y | 1 |
| Abrams, JS; Cameron, DA; Castiglione, M; Davidson, NE; Goss, PE; Ingle, JN; Livingston, RB; Martino, S; Muss, HB; Norton, L; Palmer, MJ; Pater, JL; Perez, EA; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Tu, D | 1 |
| Kafy, S; Tulandi, T | 1 |
| Bell, R; Lewis, J | 1 |
| Lin, NU; Winer, EP | 1 |
| Eidtmann, H; Gademann, G; Hilfrich, J; Jonat, W; Kaufmann, M; von Minckwitz, G; Zuna, I | 1 |
| Gralow, JR | 1 |
| Barghout, V; Delea, T; Karnon, J | 1 |
| Carroll, C; De Nigris, E; Hind, D; Simpson, E; Ward, S; Wyld, L | 1 |
| Benedict, A; Fallowfield, L; Jones, D; Locker, G; Mansel, R | 1 |
| Basso, AD; Black, S; Kirschmeier, P; Liu, G; Liu, M; Long, BJ; Marrinan, CH; Robert Bishop, W; Taylor, SA | 1 |
| Abreu, P; Banke-Bochita, J; Goss, PE; Hadji, P; Subar, M; Thomsen, T | 1 |
| Kamby, C; Lindberg, H; Nielsen, DL; Tuxen, M | 1 |
| Cufer, T | 1 |
| Fabian, CJ | 1 |
| O'Shaughnessy, J | 1 |
| Perez, EA | 1 |
| Jahanzeb, M | 1 |
| Schagen, SB; Schilder, CM | 1 |
| Borg, S; De Lafontan, B; Laroche, M; Lassoued, S; Roché, H | 1 |
| Antoni, G; Bollet, MA; Campana, F; Cottu, P; Dendale, R; Fourquet, A; Kirova, YM; Laki, F; Pierga, JY; Salmon, R; Sigal-Zafrani, B | 1 |
| Altundag, K; Dizdar, O; Harputluoglu, H | 1 |
| Brodie, AM; Buzdar, AU; Come, SE; Coombes, RC; Goss, PE; Ingle, JN; Johnston, SRD; Miller, WR; Pritchard, KI; Winer, EP; Zujewski, JA | 1 |
| Prowell, TM; Stearns, V | 1 |
| Dadak, C; Gnant, M; Greil, R; Hofbauer, F; Jakesz, R; Kubista, E; Kwasny, W; Mlineritsch, B; Renner, K; Rücklinger, E; Samonigg, H; Schmid, M; Stierer, M; Tausch, C | 1 |
| Akiyama, F; Ikeda, T; Imoto, S; Inaji, H; Kurosumi, M; Noguchi, S; Sakamoto, G; Takatsuka, Y; Tsuda, H; Watanabe, T | 1 |
| Wengström, Y | 1 |
| Baum, M; Buzdar, A; Cuzick, J; Forbes, JF; Howell, A; Tobias, JS | 1 |
| Eisen, A; Messersmith, H; Pritchard, KI; Shelley, W; Trudeau, M | 1 |
| Miller, WR | 1 |
| Toi, M | 1 |
| Allred, C; Bishop, H; Buzdar, A; Carder, P; Cussac, AL; Cuzick, J; Dowsett, M; Ellis, I; Forbes, J; Houghton, J; Knox, F; Knox, J; Larsimont, D; Mallon, E; Quinn, E; Salter, J; Sasano, H; Speirs, V; Wale, C; Williams, N | 1 |
| Blackwell, KL; Herold, CI | 2 |
| Carpenter, R | 1 |
| Adams, JE; Beckmann, MW; Clack, G; Coleman, RE; Cuzick, J; Eastell, R; Hannon, RA; Howell, A; Mackey, JR | 1 |
| Aapro, M | 1 |
| Pennery, E | 1 |
| Ucci, G | 1 |
| Coates, A; Mouridsen, H; Thürlimann, B | 1 |
| A'Hern, RP; Cameron, DA; Dixon, JM; Dowsett, M; Folkerd, E; Macaskill, EJ; McHugh, M; Murray, J; Renshaw, L; Young, O | 1 |
| A'hern, R; Banerjee, S; Dowsett, M; Ghazoui, Z; Martin, LA; Pancholi, S; Smith, IE | 1 |
| Eisner, A; Falardeau, J; Toomey, MD; Vetto, JT | 1 |
| Adrover, E; Barnadas, A; Calvo, L; de la Haba, J; Estevez, LG; Gil, M; Llombart, A; Sánchez-Rovira, P | 1 |
| Fields, MM; Mellington, TE | 1 |
| Gligorov, J; Nabholtz, JM | 1 |
| Chen, S; Lui, K; Mori, T; Tamura, T; Zhou, D | 1 |
| Bogliolo, S; Costantini, S; Dugnani, MC; Ferrero, S; Moioli, M; Papadia, A; Valenzano Menada, M | 1 |
| Grossman, J; Hahn, BH; La Cava, A; Wong, M | 1 |
| Nagykálnai, T | 1 |
| Kahán, Z | 1 |
| Bianco, AR; Buzdar, AU; Cuzick, J; Eastell, R; Forbes, JF; Sapunar, F; Sestak, I | 1 |
| Eisner, A; Falardeau, J; Thielman, EJ; Vetto, JT | 1 |
| Bjelic-Radisic, V; Dubsky, P; Fitzal, F; Gnant, M; Greil, R; Jakesz, R; Kainberger, F; Kässmann, H; Kubista, E; Luschin-Ebengreuth, G; Marth, C; Menzel, C; Mittlböck, M; Mlineritsch, B; Piswanger-Sölkner, JC; Ploner, F; Samonigg, H; Seifert, M; Steger, G; Wohlmuth, P | 1 |
| Chlebowski, RT | 2 |
| Chlebowski, RT; Col, N | 1 |
| Gurwitz, D; Newman, W | 1 |
| A'Hern, R; Bhatnagar, AS; Chaudri Ross, HA; Dowsett, M; Eiermann, W; Ellis, MJ; Evans, DB; Luo, J; Miller, WR; Smith, I; Tao, Y; von Kameke, A | 1 |
| Boyle, F; Butow, P; Coates, A; Forbes, JF; Juraskova, I; Lopez, A; McCarthy, N; Reaby, L; Seccombe, M | 1 |
| Cella, D; Cuzick, J; Fallowfield, L; Sestak, I | 1 |
| Baum, M; Cuzick, J; Distler, W; Duffy, SR; Howell, A | 1 |
| Needleman, SJ; Tobias, JS | 1 |
| Bielajew, C; Collins, B; Mackenzie, J; Stewart, A; Verma, S | 1 |
| Callam, M; Glen, J; Thomas, RJ; Williams, M | 1 |
| Albert, US; Hadji, P; Holzhauer, W; Kalder, M; Wagner, U; Ziller, M; Ziller, V | 1 |
| Bjelic-Radisic, V; Dubsky, P; Eidtmann, H; Fitzal, F; Fridrik, M; Gnant, M; Greil, R; Hubalek, M; Jakesz, R; Kwasny, W; Luschin-Ebengreuth, G; Marth, C; Menzel, C; Mlineritsch, B; Pöstlberger, S; Rücklinger, E; Samonigg, H; Schippinger, W; Seifert, M; Steger, G; Stierer, M; Tausch, C | 1 |
| Alacacioğlu, A; Bilgi, O; Erikçi, AA; Kandemir, EG; Karagöz, B; Ozgün, A; Sayan, O | 1 |
| Azria, D; Belkacémi, Y; Gligorov, J; Jacot, W; Ozsahin, M; Romieu, G; Zaman, K | 1 |
| Cobb, P; Henry, D; Houts, AC; Kulig, K; Schwartzberg, LS; Senecal, F; Stepanski, EJ; Walker, MS | 1 |
| Akashi-Tanaka, S; Ando, M; Fujiwara, Y; Hojo, T; Katsumata, N; Kinoshita, T; Kouno, T; Shibata, T; Shien, T; Shimizu, C; Terada, K; Yoshida, M; Yoshimura, K | 1 |
| Jinta, E; Sakurai, T; Shimizu, S; Suzuma, T; Umemura, T; Yoshimura, G | 1 |
| Wenz, F | 1 |
| Aebi, S; Gelber, RD | 1 |
| Calabrich, A; Katz, A; Saad, ED | 1 |
| Gerber, B; Reimer, T | 1 |
| Dong, PW; Li, LN | 1 |
| Agrawal, A; Aleskandrany, M; Cheung, KL; Ellis, IO; Green, AR; Hassell, K; Morgan, DA; Okunade, G; Paish, EC; Winterbottom, L; Ying, M | 1 |
| Fischgräbe, J; Götte, M; Kiesel, L; Radke, I; Smollich, M; Wülfing, P | 1 |
| Bachleitner-Hofmann, T; Blaha, P; Dubsky, P; Fitzal, F; Gnant, M; Jakesz, R; Steger, G | 1 |
| Amakye, D; Bauerfeind, I; Buzdar, A; Chia, S; Chlebowski, R; Cutuli, B; Cuzick, J; Hadji, P; Linforth, R; Maass, N; Noguchi, S; Robidoux, A; Verma, S | 1 |
| Cuzick, J; Sapunar, F; Sestak, I | 1 |
| Gobello, C; Gonzalez, G; Guendulain, C; Maffrand, C | 1 |
| Noguchi, S; Taguchi, T | 1 |
| Lazarus, P; Sun, D | 1 |
| Bonanni, B; Cassano, E; Cazzaniga, M; Decensi, A; Gandini, S; Guerrieri-Gonzaga, A; Johansson, H; Lien, EA; Luini, A; Macis, D; Oldani, S; Pelosi, G; Serrano, D | 1 |
| Chen, S; Masri, S; Phung, S; Wang, X | 1 |
| Dixon, JM; Hannon, R; Macaskill, EJ; McCaig, FM; McHugh, M; Murray, J; Renshaw, L; Williams, L; Young, O | 1 |
| Baumann, CK; Castiglione-Gertsch, M | 1 |
| Brodie, A; Chen, S; Fischgräbe, J; Götte, M; Kiesel, L; Macedo, LF; Radke, I; Smollich, M; Wülfing, P | 1 |
| Aldemir, M; Altuğ, U; Cakan, M; Topcuoglu, M | 1 |
| Beriwal, S; Bhargava, R; Dabbs, DJ; O'Connor, SM | 1 |
| Baehner, FL; Baum, M; Bugarini, R; Buzdar, A; Cuzick, J; Dowsett, M; Dunbier, A; Forbes, J; Howell, A; Mallon, EA; Quinn, E; Salter, J; Shak, S; Wale, C | 1 |
| Maidment, SL | 1 |
| Crossley, M; Lejbak, L; Vrbancic, M | 1 |
| Beckmann, MW; Benedict, A; Buchholz, S; Distler, W; Hadji, P; Harbeck, N; Jonat, W; Kaufmann, M; Kreienberg, R; Kreif, N; Lux, MP; Possinger, K; Raab, G; Schneeweiss, A; Tesch, H; Weyers, G; Wöckel, A | 1 |
| Abe, H; Aihara, T; Aogi, K; Hisamatsu, K; Hozumi, Y; Imoto, S; Ito, T; Iwata, H; Masuda, N; Mitsuyama, S; Mukai, H; Nakagami, K; Ogino, N; Ohashi, Y; Ohsumi, S; Shimizu, C; Takatsuka, Y; Tamura, M; Tanaka, S; Watanabe, T; Yamaguchi, T | 1 |
| Fox, KR | 1 |
| Cuzick, J; Distler, W; Dowsett, M; Forbes, JF; Howell, A; Sestak, I | 1 |
| Goodwin, PJ; Pritchard, KI | 1 |
| Beckmann, MW; Gnant, M; Jonat, W; Kreienberg, R; Lux, MP; Reichelt, C; Thiel, FC; Wallwiener, D | 1 |
| Mouridsen, HT | 1 |
| Agrawal, K; Mortimer, JE; Onami, S; Pal, SK | 1 |
| Bianco, AR; Clack, G; Duffy, S; Jackson, TL; Lansdown, M; Philips, K; Wells, M | 1 |
| Beer, B; Hubalek, M; Meraner, V; Oberacher, H; Oberguggenberger, A; Schubert, B | 1 |
| Dixon, JM; Dixon, OM; Fallowfield, LJ; Langridge, C; Macaskill, EJ; McCaig, F; McHugh, M; Murray, J; Renshaw, L; Williams, L; Young, OE | 1 |
| Agrawal, A; Cheung, KL; Dowsett, M; Folkerd, E; Robertson, JF; Winterbottom, L | 1 |
| Mylander, WC; Rosman, M; Tafra, L | 1 |
| Amant, F; Berteloot, P; Blomme, C; De Jonge, E; Depypere, H; Neven, P; Timmerman, D; Van Calster, B; Van de Putte, G; Van den Broecke, R; Van Ginderachter, J; Van Huffel, S; Vergote, I; Vlaemynck, G; Vlasselaer, J | 1 |
| Facina, G; Gebrim, LH; Logullo, AF; Mattar, A; Nonogaki, S; Soares, FA | 1 |
| Buzdar, AU; Kelly, CM | 2 |
| Adams, J; Beckmann, MW; Clack, G; Coleman, RE; Cuzick, J; Eastell, R; Howell, A; Mackey, J | 1 |
| Tang, SC | 1 |
| Inaji, H; Ishitobi, M; Komoike, Y; Koyama, H; Motomura, K; Nagase, H; Noguchi, S | 1 |
| Baum, M; Buzdar, A; Cuzick, J; Dowsett, M; Forbes, JF; Howell, A; Sestak, I | 1 |
| Gnant, M | 1 |
| Kawachi, H; Kubota, K; Kuwayama, T; Nakagawa, T; Oda, G; Sato, T; Sugihara, K; Yamamoto, K | 1 |
| Christiaens, MR; De Smet, L; Dieudonné, AS; Henry, NL; Leunen, K; Lintermans, A; Morales, L; Neven, P; Pans, S; Paridaens, R; Timmerman, D; Van Calster, B; Van Hoydonck, M; Vergote, I; Verhaeghe, J; Verschueren, K; Westhovens, R; Wildiers, H | 1 |
| Inaji, H; Ishitobi, M; Komoike, Y; Koyama, H; Motomura, K; Nakahara, S | 1 |
| Aihara, T; Hozumi, Y; Masuda, N; Ohashi, Y; Ohsumi, S; Saito, T; Suemasu, K; Takehara, M; Takei, H | 2 |
| Anderson, H; Arteaga, CL; Balko, JM; Dowsett, M; Dunbier, A; Ghazoui, Z; González-Angulo, AM; Miller, TW; Miller, WR; Mills, GB; Shyr, Y; Wu, H | 1 |
| Aihara, T; Hozumi, Y; Mukai, H; Ohashi, Y; Ohsumi, S; Shimozuma, K; Shinji, M; Takatsuka, Y | 1 |
| Doughty, JC | 1 |
| Tannock, IF | 1 |
| Arun, B; Brown, PH; Castiglione, M; Cuzick, J; DeCensi, A; Dunn, B; Forbes, JF; Glaus, A; Howell, A; Vogel, V; von Minckwitz, G; Zwierzina, H | 1 |
| Buzdar, AU; Cuzick, J; Dowsett, M; Forbes, J; Howell, A; Mallon, E; Pineda, S; Salter, J; Zabaglo, L | 1 |
| Baigent, A; Lashen, H | 1 |
| Coombes, RC; Dowsett, M; Folkerd, EJ; Palmieri, C; Purohit, A; Reed, MJ; Stanczyk, FZ; Stanway, SJ; Ward, R | 1 |
| Bjelic-Radisic, V; Dubsky, P; Fesl, C; Gnant, M; Greil, R; Königsberg, R; Marth, C; Mlineritsch, B; Pfeiler, G; Pöstlberger, S; Samonigg, H; Seifert, M; Singer, CF; Steger, GG; Stoeger, H; Taucher, S | 1 |
| Bauernhofer, T; Dubsky, P; Eidtmann, H; Eiermann, W; Fesl, C; Forsthuber, EP; Gnant, M; Greil, R; Heck, D; Hochreiner, G; Hubalek, M; Jakesz, R; Kwasny, W; Luschin-Ebengreuth, G; Menzel, C; Mlineritsch, B; Pristauz, G; Seifert, M; Steger, G; Stoeger, H | 1 |
| Allawi, Z; Baum, M; Cuzick, J | 1 |
| Ciruelos Gil, EM; Fernández Martínez, R; Fernández Pérez, I; Garcerá Juan, S; Illarramendi Mañas, JJ; Iranzo González Cruz, V; Lao Romera, J; Peláez Fernández, I; Puertolas Hernández, TJ; Sampedro Gimeno, T | 1 |
| Alba Conejo, E; Bayo Calero, J; de la Cabeza Lomas Garrido, M; de la Haba Rodríguez, J; de Toro Salas, R; González Mancha, R; Martínez Guisado, A; Ruíz Borrego, M; Sánchez Muñoz, A | 1 |
| Champ, C; Gower-Thomas, K; Jones, M; Osborn, G; Vaughan-Williams, E | 1 |
| Hurria, A | 1 |
| Baum, M; Buzdar, A; Cuzick, J; Dowsett, M; Forbes, JF; Howell, A; Ring, A; Sestak, I | 1 |
| Bago-Horvath, Z; Böhm, G; Dubsky, P; Filipits, M; Gnant, M; Greil, R; Gruber, C; Haid, A; Jakesz, R; Jasarevic, Z; Jelen, A; Kemmerling, R; Pöstlberger, S; Rudas, M; Singer, CF | 1 |
| Schmidt, C | 1 |
| Hutschemaekers, S; Nieuwenhuijzen, GA; Roukema, JA; Tjan-Heijnen, VC; van der Sangen, MJ; Voogd, AC; Wink, CJ; Woensdregt, K | 1 |
| A'Hern, R; Anderson, H; Bliss, J; Dowsett, M; Dunbier, A; Evans, A; Ghazoui, Z; Iskender, A; Johnson, L; Pinhel, I; Robertson, J; Robison, L; Salter, J; Skene, T; Smith, I; Wilcox, M | 1 |
| Akiyama, F; Fujiwara, Y; Ikeda, T; Imoto, S; Inaji, H; Iwata, H; Mitsuyama, S; Miyoshi, K; Noguchi, S; Takatsuka, Y; Tamura, M | 1 |
| Hawkins, N; Veenstra, D; Woods, B | 1 |
| Costantino, JP; Goss, PE; Ingle, JN; Jenkins, GD; Kubo, M; McDonnell, SK; Schaid, DJ; Sinnwell, JP; Weinshilboum, RM; Wickerham, DL | 1 |
| Hozumi, Y; Ohashi, Y; Ohsumi, S; Shimozuma, K; Suemasu, K; Takehara, M; Takei, H | 1 |
| Frederix, GW; Hövels, AM; Raaijmakers, JA; Schellens, JH; Severens, JL | 1 |
| Iwase, H; Iwata, H; Kamigaki, S; Kinoshita, T; Masuda, N; Nakamura, S; Nishimura, R; Noguchi, S; Sagara, Y; Takei, H; Yanagita, Y | 1 |
| Burstein, HJ; Griggs, JJ | 1 |
| Bartsch, R; Dubsky, PC; Filipcic, L; Fitzal, F; Gnant, M; Greil, R; Haider, K; Jakesz, R; Kwasny, W; Luschin-Ebengreuth, G; Mlineritsch, B; Pöstlberger, S; Rudas, M; Samonigg, H; Sevelda, P; Singer, CF; Steger, GG; Stierer, M; Stöger, H; Taucher, S; Tausch, C | 1 |
| Cuzick, J; Dowsett, M; Drury, S; Hayes, DF; Haynes, BP; Rae, JM; Salter, J; Sestak, I; Stearns, V; Thibert, JN | 1 |
| Brown, M; Cuzick, J; Dowsett, M; Howell, A; Landberg, G; Lundgren, K; Pineda, S; Salter, J; Zabaglo, L | 1 |
| Cuzick, J; Dowsett, M; Forbes, JF; Harvie, M; Howell, A; Sestak, I | 1 |
| Mewar, D; Michael, B; Tunn, E; Williams, S | 1 |
| Acar, H; Ata, O; Toy, H; Yavas, C; Yavas, G; Yuce, D | 1 |
| Hayashi, N; Iwase, H; Iwata, H; Kamigaki, S; Kinoshita, T; Masuda, N; Nakamura, S; Nishimura, R; Noguchi, S; Sagara, Y; Takei, H; Tsuda, H; Yanagita, Y | 1 |
| Bachner, M; Brase, JC; Dietze, O; Dubsky, P; Filipits, M; Gehrmann, MC; Gnant, M; Greil, R; Jakesz, R; Klug, E; Kronenwett, R; Luisser, I; Mayr, D; Petry, C; Rudas, M; Schmidt, M; Sedivy, R; Singer, CF; Weber, KE | 1 |
| Magee, PJ; Rowland, I | 1 |
| Garcia, PL; Gomes, FP | 1 |
| Tung, N | 1 |
| Bong, JG; Jeong, YJ; Kwon, HJ; Park, SH; Park, YS; Shin, IH | 1 |
| Boccardo, F; Bordonaro, R; Fini, A; Guglielmini, P; Massidda, B; Orzalesi, L; Porpiglia, M; Roagna, R; Rubagotti, A; Serra, P; Ucci, G | 1 |
| Anan, K; Higaki, K; Mase, T; Nishimura, R; Ohno, S; Sagara, Y; Shibuta, K; Tanaka, M; Teramukai, S; Tsuyuki, S; Yamamoto, Y | 1 |
| Aapro, M; Bartlett, JM; Coleman, RE; Markopoulos, C; Putter, H; van de Velde, CJ | 1 |
| Banerjee, M; Gersch, C; Giacherio, D; Hayes, DF; Henry, NL; McConnell, D; Partridge, AH; Pearlman, M; Schott, AF; Stearns, V; Xia, R | 1 |
| Cowens, JW; Cuzick, J; Dowsett, M; Dunbier, AK; Ferree, S; Lopez-Knowles, E; Schaper, C; Sestak, I; Sidhu, K; Storhoff, J | 1 |
| Afentakis, M; Buzdar, A; Cuzick, J; Dowsett, M; Forbes, J; Howell, T; Salter, J; Sestak, I | 1 |
| Cuzick, J; Dowsett, M; Dunbier, A; Erlander, MG; Goss, PE; Lopez-Knowles, E; Schnabel, CA; Schroeder, B; Sestak, I; Sgroi, DC; Sidhu, K; Zhang, Y | 1 |
| Gebrim, LH; Logullo, AF; Madeira, M; Mattar, A; Soares, FA | 1 |
| Bachner, M; Brase, JC; Dietze, O; Dubsky, P; Filipits, M; Fisch, K; Gehrmann, MC; Gnant, M; Greil, R; Jakesz, R; Klug, E; Kronenwett, R; Luisser, I; Mayr, D; Petry, C; Rudas, M; Schmidt, M; Sedivy, R; Singer, CF; Weber, KE | 1 |
| Mehta, A; Tripathy, D | 1 |
| Bulun, SE; Khan, SA; Lin, Z; Moy, I; Rademaker, AW; Reierstad, S | 1 |
| Frederix, GW; Hövels, AM; Huitema, AD; Raaijmakers, JA; Schellens, JH; Severens, JL; van Hasselt, JG | 1 |
| Bago-Horvath, Z; Balic, M; Bartsch, R; Cowens, JW; Dubsky, P; Ferree, S; Fesl, C; Filipits, M; Fitzal, F; Gnant, M; Greil, R; Jakesz, R; Knauer, M; Kwasny, W; Liu, S; Mlineritsch, B; Nielsen, TO; Ressler, S; Rudas, M; Schaper, C; Singer, C; Steger, G; Stoeger, H; Storhoff, J | 1 |
| Boyle, F; Bulsara, M; Holman, CD; Kemp, A; Malacova, E; Preen, DB; Roughead, EE; Saunders, C | 1 |
| Cutress, RI; Layfield, DM; Mohamud, M; Odofin, O; Royle, GT; Walsh, C | 1 |
| Angelucci, D; Ausili Cefaro, G; Cianchetti, E; Cioffi, P; De Tursi, M; Di Nicola, M; Grassadonia, A; Grossi, S; Iacobelli, S; Iezzi, L; Marinelli, C; Natoli, C; Noccioli, P; Politi, R; Tavoletta, S; Tinari, N; Zilli, M | 1 |
| A'Hern, R; Afentakis, M; Arnedos, M; Dowsett, M; Drury, S; Hills, M; Reis-Filho, JS; Salter, J; Smith, IE | 1 |
| Brufsky, AM | 1 |
| Agrawal, A; Cheung, KL; Gutteridge, E; Marenah, C; Mathew, J; Prinsloo, P; Robertson, JF | 1 |
| Dryden, R; Harrow, A; McCowan, C; Parsons, M; Radley, A; Thompson, AM; Wells, M | 1 |
| Chen, D; Deng, Y; Feng, G; He, P; Hu, R; Huang, T; Li, E; Li, L; Li, Y; Liang, Z; Lin, Y; Liu, J; Lu, Y; Ma, R; Su, F; Sun, S; Tong, Z; Wang, S; Wang, X; Wu, Y; Xu, Z; Zhang, H; Zhang, X; Zhang, Y; Zhao, Y | 1 |
| Andò, S; Barone, I; Brown, PH; Fuqua, SA; Iacopetta, D; O'Malley, BW; Rechoum, Y; Rovito, D; Weigel, NL | 1 |
| Campos-Gómez, S; Chapa-Ibargüengoitia, M; de la Peña-Lopez, R; Dorantes-Heredia, R; Flores-Arredondo, JH | 1 |
| Billen, J; Christiaens, MR; Jans, I; Laenen, A; Lintermans, A; Neven, P; Paridaens, R; Pauwels, S; Van Asten, K; Van Herck, E; Vanderschueren, D; Verhaeghe, J; Vermeersch, P; Wildiers, H | 1 |
| Armengol-Alonso, A; Dalmau, E; Muñoz, M; Seguí-Palmer, MÁ | 1 |
| Aihara, T; Andoh, M; Aogi, K; Fukuuchi, A; Hozumi, Y; Iwata, H; Kim, R; Makino, H; Mukai, H; Ohashi, Y; Ohno, S; Takatsuka, Y; Tamura, M; Tsugawa, K; Watanabe, T; Yamaguchi, T; Yokota, I | 1 |
| Cowens, JW; Cuzick, J; Dowsett, M; Dubsky, P; Ferree, S; Fesl, C; Filipits, M; Gnant, M; Lopez-Knowles, E; Schaper, C; Sestak, I | 1 |
| Albertini, S; Kelly, E; Lu, CY; Vitry, A | 1 |
| Abehsera, D; de Santiago, J; Panal, M; Revello, R; Sánchez-Mendez, JI; Zapardiel, I | 1 |
| Balic, M; Bartsch, R; Bjelic-Radisic, V; Dubsky, P; Eidtmann, H; Eiermann, W; Fesl, C; Fitzal, F; Gnant, M; Greil, R; Hochreiner, G; Jakesz, R; Knauer, M; Kwasny, W; Luschin-Ebengreuth, G; Mlineritsch, B; Moik, M; Ploner, F; Seifert, M; Selim, U; Sevelda, P; Steger, G; Stoeger, H; Taucher, S; Wette, V | 1 |
| Atkins, L; Barni, S; Deschamp, V; Franquet, A; Gnant, M; Kreienberg, R; Markopoulos, C; Marty, M; Neciosup, S; Neven, P; Tanner, M; Tesarova, P | 1 |
| Barbie, TU; Ma, C; Margenthaler, JA | 1 |
| Bevers, TB | 1 |
| Balic, M; Cowens, JW; Cuzick, J; Dowsett, M; Dubsky, P; Ferree, S; Fesl, C; Filipits, M; Gnant, M; Greil, R; Jakesz, R; Lopez-Knowles, E; Nielsen, T; Rudas, M; Schaper, C; Sestak, I; Stoeger, H | 1 |
| Chang, CH; Chen, SJ; Liu, CY | 1 |
| Audisio, R; Cheung, KL; Collins, K; Morgan, JL; Reed, MW; Robinson, TG; Wyld, L | 1 |
| Bonneterre, J; Delbeuck, X; Kramar, A; Le Rhun, E; Lefeuvre-Plesse, C; Pasquier, F; Skrobala, E | 1 |
| Buist, MR; Kenter, GG; van der Velden, J; van Driel, WJ; van Lonkhuijzen, LR; van Meurs, HS | 1 |
| Colleoni, M; Munzone, E | 1 |
| Dowsett, M; Yeo, B | 1 |
| Kuerer, H; Mitchell, KB | 1 |
| Akyol, M; Alacacioglu, A; Bayoglu, V; Demir, L; Dirican, A; Ellidokuz, H; Gumus, Z; Kucukzeybek, B; Kucukzeybek, Y; Salman, T; Sutcu, R; Tarhan, MO; Varol, U; Yildiz, I; Yildiz, Y | 1 |
| Bonanni, B; Bundred, N; Coleman, RE; Cuzick, J; Eiermann, W; Ellis, I; Forbes, JF; Holcombe, C; Howell, A; Jones, L; Levy, C; Neven, P; Sestak, I; Stierer, M; von Minckwitz, G | 1 |
| Albain, KS; Brufsky, AM; Cecchini, RS; Cianfrocca, ME; Costantino, JP; Fehrenbacher, L; Ganz, PA; Gross, HM; Hopkins, JO; Julian, TB; Mamounas, EP; Margolese, RG; Seay, TE; Soori, GS; Sturtz, K; Vallow, LA; Whitworth, PW; Wolmark, N; Wozniak, TF | 2 |
| Callet, N; Fourme, E; Noguès, C; Reyal, F; Sénéchal, C; Stoppa-Lyonnet, D; This, P | 1 |
| Berishaj, M; Bonafé, M; Bowman, RL; Bromberg, J; Ceccarelli, C; Chang, Q; Chen, J; Colameco, C; Cricca, M; Daly, L; DeMichele, A; Fabbri, N; Feldman, M; Gasparre, G; Healey, JH; Lyden, D; Mao, JJ; Nnoli, J; Perna, F; Rajasekhar, VK; Sansone, P; Santini, D; Shih, NN; Taffurelli, M; Vidone, M | 1 |
| Amaral, C; Correia-da-Silva, G; Sobral, AF; Teixeira, N | 1 |
| Cuzick, J; Dowsett, M; Schnabel, CA; Schroeder, BE; Sestak, I; Sgroi, D; Zhang, Y | 1 |
| Gilarranz, YJ; Lopez-Tarruella, S; Martin, M | 1 |
| Altinok, AY; Altug, T; Azria, D; Bese, NS; Ober, A; Ozsahin, EM; Sut, N; Yildirim, S | 1 |
| Buus, R; Cuzick, J; Denkert, C; Dowsett, M; Dubsky, P; Krappmann, K; Kronenwett, R; Petry, C; Scheer, M; Sestak, I | 1 |
| Brufsky, AM; Davidson, NE | 1 |
| Arpino, G; De Placido, G; De Placido, S; De Rosa, P; Locci, M; Nazzaro, G; Pagano, T; Schettini, F; Vallone, R | 1 |
| Baron, P; Beatty, J; Beitsch, P; de Snoo, FA; Dul, CL; Lee, LA; Mislowsky, A; Murray, M; Nash, C; Pellicane, JV; Rotkis, M; Stork-Sloots, L; Whitworth, P | 1 |
| Bodurka, DC; Coleman, RL; Gershenson, DM; Lu, KH; Malpica, A; Sun, CC | 1 |
| Corrigan, MA; Jinih, M; O'Reilly, S; Redmond, HP; Relihan, N | 1 |
| Giorgadze, E; Khachidze, N; Tsagareli, M | 1 |
| Alvarez, CA; Balasubramian, BA; Jean, GW; Murphy, CC; Tiro, JA | 1 |
| Cohen, PR | 1 |
| Carpenter, NA; Crook, EK | 1 |
| Pan, W; Sun, X; Tang, X; Wu, S; Yang, Y | 1 |
| Ahmed, I; Bartlett, JMS; Brookes, CL; Cuzick, J; Dell'Orto, P; Dowsett, M; Forbes, JF; Mallon, EA; Putter, H; Rea, DW; Regan, MM; Sestak, I; Seynaeve, C; Thürlimann, B; Van de Velde, CJH; Viale, G | 1 |
| Ellis, MJ; Goncalves, R; Reinert, T | 1 |
| Andrade, DB; Barros-Oliveira, MDC; Borges, RS; Borges, US; Costa-Silva, DR; Silva, BBD; Silva, JM; Tavares, CB | 1 |
| Hong, N; Kim, SI; Park, S; Rhee, Y; Seo, DH; Sohn, JH; Yoon, HG | 1 |
| Armstrong, DK; Bergstrom, J; DeBernardo, R; Fader, AN; Gaillard, S; Jernigan, A; Levinson, KL; Michener, C; Ricci, S; Roche, KL; Rose, PG; Shih, IM; Stone, RL; Tanner, EJ; Wang, TL; Wethingon, S; Yang, B; Zhang, G | 1 |
| Austin, ED; Brittain, EL; Chen, X; Farber-Eger, EH; Fessel, JP; Hemnes, AR; Loyd, JE; Talati, M; West, J | 1 |
| He, Y; Huang, Y; Wang, C; Wu, K; Zhang, J; Zheng, S | 1 |
| Cuzick, J; Dowsett, M; Heindl, A; Naidoo, K; Sestak, I; Yuan, Y | 1 |
| de Boer, M; De Graaf, H; de Roos, WK; Erdkamp, FLG; Honkoop, AH; Imholz, ALT; Kroep, JR; Linn, SC; Peer, PGM; Seynaeve, CM; Smorenburg, CH; Swinkels, ACP; Tjan-Heijnen, VCG; van den Berkmortel, FWPJ; van der Sangen, MJC; van Hellemond, IEG | 2 |
| Cuzick, J; Forbes, JF; Howell, A; Sestak, I; Smith, SG | 1 |
| Chung, C | 1 |
| Clayman, E; Huber, KM; Kumar, A; Smith, P | 1 |
| Baehner, FL; Buus, R; Cuzick, J; Denkert, C; Dowsett, M; Dubsky, P; Ferree, S; Kronenwett, R; Mallon, E; Schnabel, C; Sestak, I; Sgroi, D | 1 |
| Amoroso, D; Arpino, G; Bernardo, A; Bisagni, G; Carlini, P; Cognetti, F; Cogoni, AA; De Laurentiis, M; De Placido, S; Del Mastro, L; Foglietta, J; Frassoldati, A; Gallo, C; Gori, S; Gravina, A; Lai, A; Laudadio, L; Lauria, R; Lorusso, V; Mocerino, C; Montemurro, F; Moretti, G; Moscetti, L; Nuzzo, F; Perrone, F; Riccardi, F; Rizzo, S; Russo, A; Sarobba, MG; Verusio, C | 1 |
| Dirix, LY | 1 |
| de Boer, M; de Graaf, H; de Roos, WK; Erdkamp, FLG; Honkoop, AH; Imholz, ALT; Kitzen, JJEM; Kroep, JR; Linn, SC; Peer, PGM; Seynaeve, CM; Smorenburg, CH; Swinkels, ACP; Tjan-Heijnen, VCG; van den Berkmortel, FWPJ; van der Sangen, MJC; van Hellemond, IEG; Vriens, IJH | 1 |
| Evans, DG; Howell, A; Howell, SJ | 1 |
| Colleoni, M; Cuzick, J; Dodson, A; Dowsett, M; Regan, MM; Sestak, I; Thürlimann, B; Viale, G | 1 |
| Brentnall, AR; Buus, R; Cheang, MCU; Cuzick, J; Dowsett, M; Gao, Q; Khabra, K; Klintman, M; Sestak, I; Yeo, B | 1 |
| Ahn, JH; Ahn, JS; Im, SA; Im, YH; Jung, KH; Kim, GM; Kim, JH; Kim, JY; Kim, S; Kim, SB; Kim, SH; Kim, TY; Lee, KH; Lee, KS; Park, IH; Park, YH; Ro, J; Sohn, J | 1 |
| Chang, B; Fan, X; Jiang, X; Kariminia, S; Li, L; Li, Q; Li, T; Li, Y; Wu, S; Zhang, J | 1 |
| Bailey, C; Birkett, J; De Grève, J; De Vos, FYFL; Dean, E; Dirix, L; Goessl, C; Grundtvig-Sørensen, P; Italiano, A; Jerusalem, G; Learoyd, M; Leunen, K; Molife, LR; Plummer, R; Rolfo, C; Rottey, S; Spencer, S; Spicer, J; Verheul, HM | 1 |
| Kamaraju, S; Laud, P; Nattinger, AB; Neuner, J; Shi, Y; Smith, E | 1 |
| Drokow, EK; Li, Z; Liu, J; Ma, X; Ren, J; Shao, S; Shi, X; Tan, L; Xue, C; Yan, Y; Zhang, L; Zhang, X; Zhang, Y | 1 |
| Boyd, R; Campbell, AM; Carson, H; Elliott, C; Gallagher, R; Harkin, DP; McIntosh, SA; Morris, M; Savage, KI; Wielogorska, E | 1 |
| de Boer, M; de Graaf, H; de Roos, WK; Erdkamp, FLG; Honkoop, AH; Imholz, ALT; Kroep, JR; Linn, SC; Peer, PGM; Seynaeve, CM; Smorenburg, CH; Swinkels, ACP; Tjan-Heijnen, VCG; van den Berkmortel, FWPJ; van der Sangen, MJC; van Hellemond, IEG; Vriens, IJH | 1 |
| Beijnen, JH; de Jong, KAM; de Vries, N; Rosing, H; van Nuland, M; Venekamp, N | 1 |
| Augustine, TN; Chetty, N; Dix-Peek, T; Duarte, R; Pather, K | 1 |
| Daniels, B; Pearson, SA; Preen, DB; Tang, M; Tervonen, HE | 1 |
| Alarid, ET; Arendt, LM; Beebe, DJ; Johnson, BP; Morgan, MM | 1 |
| DiNardo, D; Farkas, A; Merriam, S; Vanderberg, R | 1 |
| Barron, S; Buus, R; Cuzick, J; Dowsett, M; Dynoodt, P; Fender, B; Gallagher, WM; Loughman, T; O'Leary, D; Ruiz, CL; Sestak, I; Wang, CA | 1 |
| Chumsri, S; Thompson, EA | 1 |
| Chen, J; Fan, Y; He, T; Huang, Q; Li, P; Lv, Q; Wu, Y; Xiang, M; Yang, D; Yang, W; Zhang, X; Zhou, R | 1 |
| Carpi, A; Ferrari, P; Morganti, R; Nicolini, A; Rossi, G | 1 |
| Petit, T | 1 |
| Aebersold, DM; Albrecht, C; Böhmer, D; Flentje, M; Ganswindt, U; Ghadjar, P; Höcht, S; Hölscher, T; Müller, AC; Niehoff, P; Pinkawa, M; Sedlmayer, F; Wiegel, T; Zips, D | 1 |
| Duma, MN; Krug, D | 1 |
| Avarisli, NA; Bicer, BK; Bicer, T; Dogan, AS; Gurdal, C; Imamoglu, GI; Kabatas, N | 1 |
| Schenke, H; Trabitzsch, J | 1 |
| DiNome, ML; Ganz, PA; Graham, D | 1 |
| Baehner, FL; Buus, R; Cuzick, J; Dowsett, M; Ferree, S; Kronenwett, R; Mallon, EA; Schnabel, CA; Sestak, I | 1 |
| Ferracini, AC; Juliato, CRT; Mazzola, PG; Medeiros, LM; Souza, CM; Stahlschmidt, R | 2 |
| Bogliolo, S; Carletti, GV; Cassani, C; De Silvestri, A; Dominoni, M; Gardella, B; Spinillo, A | 1 |
| Balic, M; Bartsch, R; Dubsky, P; Ferree, S; Fesl, C; Filipits, M; Fitzal, F; Gnant, M; Greil, R; Herz, W; Moinfar, F; Rudas, M; Schaper, C | 1 |
| Agostinetto, E; de Azambuja, E; Debien, V; Lambertini, M; Marta, GN; Piccart-Gebhart, M | 1 |
| Gilman, EA; Hofstatter, EW; Mussallem, DM; Pruthi, S | 1 |
| Abramowitz, J; Chan, AVC; Ganji, N; Mirfakhraee, S | 1 |
| Balic, M; Bartsch, R; Bjelic-Radisic, V; Brunner, C; Deutschmann, C; Egle, D; Fesl, C; Fitzal, F; Gampenrieder, SP; Gnant, M; Greil, R; Greil-Ressler, S; Haslbauer, F; Heck, D; Jakesz, R; Kacerovsky-Strobl, S; Manfreda, D; Melbinger-Zeinitzer, E; Rinnerthaler, G; Sevelda, P; Singer, CF; Soelkner, L; Steger, GG; Suppan, C; Thaler, J; Trapl, H; Wette, V; Wieder, U; Wimmer, K | 1 |
| Bago-Horvath, Z; Balic, M; Barron, S; Dubsky, P; Egle, D; Filipits, M; Fitzal, F; Gallagher, WM; Gnant, M; Greil, R; Halper, S; Hlauschek, D; Hulla, W; Kainz, V; Loughman, T; O'Leary, D; Regitnig, P; Rudas, M; Singer, CF | 1 |
| Adams, S; Klar, N | 1 |
| Gong, S; Hong, K; Liang, JJ; Liu, TY; Qin, KM; Xie, BH; Yan, JJ; Yang, L; Yin, YP; Yu, WL; Zhou, HB | 1 |
| Ng, BP; Park, C; Park, SK; Woo, A | 1 |
| Buus, R; Chu, K; Colleoni, M; Cuzick, J; Di Fiore, PP; Disalvatore, D; Dowsett, M; Freddi, S; Maisonneuve, P; Montani, F; Pece, S; Sestak, I; Tillhon, M; Veronesi, P; Viale, G | 1 |
| Elancheran, R; Maruthanila, VL; Mirunalini, S | 1 |
| Acconcia, F | 1 |
| Han, S; Heo, JH; Mehta, S; Park, C; Spencer, JC | 1 |
| Castro, RCMB; Corpes, EF; Fernandes, AFC; Leite, KM; Martins, MCT; Santos, CPRSD; Silva, DMD; Vieira, MM; Yanez, RJV | 1 |
| Egawa, C; Hasegawa, Y; Higaki, K; Hozumi, Y; Iijima, K; Iwase, T; Komoike, Y; Masuoka, H; Mukai, H; Nakamura, T; Ohtani, S; Ohtsu, H; Saji, S; Sato, Y; Takei, H; Tanabe, M; Tanaka, M; Yanagita, Y | 1 |
| Al Hussein Al Awamlh, B; Barocas, DA; Chang, SS; Cortese, BD; Dusetzina, SB; Luckenbaugh, AN; Penson, DF; Stimson, CJ; Talwar, R | 1 |
| Salmon, RJ | 1 |
| Arnachellen, D; Augustine, TN; Pillay, K; Xulu, KR | 1 |
| Calsavara, VF; Cecchini, RS; Diniz, MA; Ganz, PA; Gresham, G; Hays, RD; Henry, NL; Kim, S; Luu, M; Rogatko, A; Tighiouart, M; Yothers, G | 1 |
| Chavez-MacGregor, M; Freedman, RA; Glass, C; Jones, A; Kantor, O; King, TA; Leonard, SJ; Mayer, EL; Mittendorf, EA; Newman, LA; Ogayo, ER | 1 |
| Mahase, E | 1 |
155 review(s) available for anastrozole and tamoxifen
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Use of aromatase inhibitors in postmenopausal women with advanced breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 1997 |
Anastrozole: a new addition to the armamentarium against advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Nitriles; Tamoxifen; Triazoles | 1998 |
The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Belgium; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Severity of Illness Index; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 1999 |
Lessons from the use of aromatase inhibitors in the neoadjuvant setting.
Topics: Aged; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 1999 |
Use of aromatase inhibitors in breast carcinoma.
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Design; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Premenopause; Tamoxifen; Triazoles | 1999 |
[Chemo/endocrine therapy for breast cancer patients].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Gonadotropin-Releasing Hormone; Humans; Nitriles; Tamoxifen; Triazoles | 2000 |
[Developments of hormonal agents for breast cancer].
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2001 |
New combinations with Herceptin in metastatic breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Interactions; Drug Synergism; Epirubicin; Female; Fluorouracil; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Nitriles; Organoplatinum Compounds; Paclitaxel; Tamoxifen; Thiotepa; Trastuzumab; Treatment Outcome; Triazoles; Vinblastine; Vinorelbine | 2001 |
Role of anti-aromatase agents in postmenopausal advanced breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2001 |
Third-generation aromatase inhibitors in the treatment of advanced breast cancer.
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
A summary of second-line randomized studies of aromatase inhibitors.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Drug Tolerance; Enzyme Inhibitors; Estrogen Receptor Modulators; Fadrozole; Female; Humans; Letrozole; Megestrol Acetate; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2001 |
A vision for the future?
Topics: Anastrozole; Breast Neoplasms; Estradiol; Female; Fulvestrant; Goserelin; Humans; Menopause; Nitriles; Tamoxifen; Triazoles | 2001 |
Preliminary data from ongoing adjuvant aromatase inhibitor trials.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Triazoles | 2001 |
Aromatase inhibitors continue their ATAC on tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2002 |
Antiaromatase agents: evolving role in adjuvant therapy.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2002 |
[The role of aromatase inhibitors in the treatment of breast neoplasms. An evaluation of clinical efficacy and the tolerability profile].
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Follow-Up Studies; Forecasting; Humans; Letrozole; Middle Aged; Nitriles; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Triazoles | 2002 |
[Antiestrogen therapy in the treatment of breast neoplasms].
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Forecasting; Humans; Indoles; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene; Triazoles | 2002 |
Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer.
Topics: Adjuvants, Pharmaceutic; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Female; Follow-Up Studies; Humans; Neoadjuvant Therapy; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2001 |
Evolving uses of hormonal agents for breast cancer therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Nitriles; Tamoxifen; Toremifene; Triazoles | 2002 |
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Enzyme Inhibitors; Evidence-Based Medicine; Expert Testimony; Female; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Triazoles | 2002 |
Anastrozole: in early breast cancer.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Therapy, Combination; Enzyme Inhibitors; Female; Half-Life; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2002 |
Breast cancer chemoprevention--an update.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Forecasting; Genes, BRCA2; Humans; Incidence; Middle Aged; Nitriles; Odds Ratio; Receptors, Estrogen; Tamoxifen; Triazoles | 2002 |
Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Approval; Female; Humans; Nitriles; Tamoxifen; Triazoles; United States | 2002 |
Adjuvant endocrine therapy in postmenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2003 |
Current and future status of adjuvant therapy for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Female; Forecasting; Humans; Nitriles; Osteoporosis; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
Is tamoxifen the Rosetta stone for breast cancer?
Topics: Acetyltransferases; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Controlled Clinical Trials as Topic; Disease-Free Survival; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Histone Acetyltransferases; Humans; Metaphor; Nitriles; Nuclear Receptor Coactivator 1; Nuclear Receptor Coactivator 3; Oncogene Proteins; Phosphorylation; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Signal Transduction; Tamoxifen; Trans-Activators; Transcription Factors; Treatment Failure; Treatment Outcome; Triazoles | 2003 |
[Present and future of adjuvant hormone therapy in breast cancer: clinical evidence and clinical trials].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2003 |
Current status of endocrine therapy for breast cancer.
Topics: Algorithms; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Chemotherapy, Adjuvant; Climacteric; Female; Goserelin; Humans; Neoplasm Metastasis; Nitriles; Tamoxifen; Triazoles | 2003 |
Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.
Topics: Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Time Factors; Treatment Outcome; Triazoles; United States | 2003 |
Is low-dose tamoxifen useful for the treatment and prevention of breast cancer?
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Estrogen Receptor Modulators; Estrogens; Female; Humans; Ki-67 Antigen; Nitriles; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2003 |
A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol Acetate; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Tamoxifen; Triazoles; Xenograft Model Antitumor Assays | 2003 |
Aromatase inhibitors in prevention--data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study).
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Prognosis; Tamoxifen; Triazoles | 2003 |
Safety issues surrounding the use of aromatase inhibitors in breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Female; Humans; Letrozole; Metabolism; Nitriles; Patient Satisfaction; Quality of Life; Safety; Tamoxifen; Triazoles | 2003 |
Should aromatase inhibitors replace tamoxifen?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2003 |
Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Evidence-Based Medicine; Female; Follow-Up Studies; Humans; Middle Aged; Nitriles; Postmenopause; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Tamoxifen; Time Factors; Triazoles | 2003 |
Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Endocrine System; Female; Humans; Menopause; Neoplasm Metastasis; Nitriles; Patient Selection; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Over Studies; Double-Blind Method; Female; Humans; Middle Aged; Multicenter Studies as Topic; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Retrospective Studies; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
[Adjuvant endocrine treatment of breast cancer beyond St. Gallen 2003].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2003 |
Role of anastrozole in adjuvant therapy for postmenopausal patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2003 |
Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Nitriles; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2003 |
New findings about endocrine therapy for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2003 |
The best use of adjuvant endocrine treatments.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Gonadotropin-Releasing Hormone; Humans; Middle Aged; Nitriles; Ovary; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
Challenges in the endocrine management of breast cancer.
Topics: Adult; Aged; Anastrozole; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Letrozole; Mastectomy, Segmental; Mice; Middle Aged; Nitriles; Prognosis; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles; United Kingdom | 2003 |
Focus on anastrozole and breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Therapy, Combination; Enzyme Inhibitors; Estrogens; Female; Goserelin; Humans; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Tamoxifen; Triazoles | 2003 |
[Neoadjuvant endocrine therapy for breast cancer: an overview].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Tamoxifen; Triazoles | 2004 |
[Controversies in endocrine therapy for breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estrogen Replacement Therapy; Female; Humans; Letrozole; Mastectomy, Segmental; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Tamoxifen; Triazoles | 2004 |
Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2004 |
Aromatase inhibitors for breast cancer in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2004 |
Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Approval; Drug Interactions; Economics, Pharmaceutical; Female; Forecasting; Geriatrics; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Patient Selection; Postmenopause; Practice Patterns, Physicians'; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles; United States; United States Food and Drug Administration | 2004 |
Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |
[Aromatase inhibitors in the adjuvant therapy of breast carcinomas].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Patient Care Management; Practice Guidelines as Topic; Practice Patterns, Physicians'; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2004 |
Current developments in hormonal therapy of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2004 |
The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial: an update.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Middle Aged; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |
Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Enzyme Inhibitors; Evidence-Based Medicine; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Tamoxifen; Triazoles | 2004 |
[Postoperative hormone (endocrine) therapy in endometrial carcinoma].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chemotherapy, Adjuvant; Drug Therapy, Combination; Endometrial Neoplasms; Estrogens; Female; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Medroxyprogesterone Acetate; Nitriles; Postoperative Care; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2004 |
Breast cancer (metastatic).
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2003 |
[Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Letrozole; Menopause; Neoplasms, Hormone-Dependent; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2004 |
Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life.
Topics: Algorithms; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Decision Trees; Drug Administration Schedule; Drug Monitoring; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Postmenopause; Quality of Life; Safety; Selective Estrogen Receptor Modulators; Social Support; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Aromatase inhibitors and breast cancer: time for a change?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Letrozole; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Nitriles; Postmenopause; Quinazolines; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Evidence-Based Medicine; Female; Humans; Letrozole; Mastectomy, Segmental; Neoadjuvant Therapy; Nitriles; Randomized Controlled Trials as Topic; Receptors, Estrogen; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Clinical applications of hormonal therapy in ovarian cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leuprolide; Medroxyprogesterone; Neoplasm Invasiveness; Neoplasm Staging; Nitriles; Ovarian Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2005 |
Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Female; Fulvestrant; Humans; Injections, Intramuscular; Neoplasm Staging; Nitriles; Postmenopause; Quality of Life; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Aromatase inhibitors for the treatment and prevention of breast cancer.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Nitriles; Randomized Controlled Trials as Topic; Risk Assessment; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2005 |
Aromatase inhibitors for therapy of advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Evaluation; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
The aromatase inhibitors in early breast cancer: who, when, and why?
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Letrozole; Nitriles; Patient Selection; Selective Estrogen Receptor Modulators; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Recurrence; Survival Rate; Tamoxifen; Triazoles | 2005 |
Adjuvant endocrine therapy in postmenopausal women with early breast cancer: where are we now?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2005 |
Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Controlled Clinical Trials as Topic; Estrogen Receptor Modulators; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Breast cancer (metastatic).
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Bridged-Ring Compounds; Female; Humans; Nitriles; Progestins; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2005 |
Adjuvant endocrine therapy in postmenopausal breast cancer patients.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2005 |
New developments in the treatment of postmenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2005 |
Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Estradiol; Female; Fulvestrant; Hormone Replacement Therapy; Humans; Lipids; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Risk Factors; Tamoxifen; Triazoles; Triglycerides | 2006 |
Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Joint Diseases; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
Defining the roles of aromatase inhibitors in the adjuvant treatment of early-stage breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Neoplasm Staging; Nitriles; Research Design; Tamoxifen; Triazoles | 2005 |
Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Estrogen Receptor Modulators; Female; Humans; Neoadjuvant Therapy; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Triazoles | 2006 |
Adjuvant endocrine therapy for postmenopausal women with early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
Anastrozole for breast cancer: recent advances and ongoing challenges.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2006 |
Time to response: comparison of fulvestrant and oral endocrine agents.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Injections, Intramuscular; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
Bone safety of aromatase inhibitors versus tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Female; Fractures, Bone; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2006 |
Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2006 |
Adjuvant therapy for patients who have node-positive breast cancer.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lymphatic Metastasis; Middle Aged; Nitriles; Postmenopause; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cholesterol; Estrogens; Female; Humans; Nitriles; Postmenopause; Risk Factors; Tamoxifen; Thromboembolism; Triazoles; Triglycerides | 2007 |
Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Tamoxifen; Triazoles | 2007 |
Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Nitriles; Quality of Life; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
Optimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Ovariectomy; Ovary; Postmenopause; Premenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2007 |
[Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
[Advancement in endocrine therapy for breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2007 |
New advances in ovulation induction.
Topics: Anastrozole; Aromatase Inhibitors; Clomiphene; Estrogen Antagonists; Female; Fertility Agents, Female; Gonadotropins; Humans; Infertility, Female; Letrozole; Nitriles; Ovary; Ovulation Induction; Pregnancy; Pregnancy Rate; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Survival Analysis; Tamoxifen; Time Factors; Triazoles | 2007 |
[Antiestrogen treatment in postmenopausal patients with metastatic breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Nitriles; Postmenopause; Prognosis; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Reducing the risk of late recurrence in hormone-responsive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Tamoxifen; Triazoles | 2007 |
The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Drug Resistance; Female; Humans; Letrozole; Musculoskeletal Diseases; Nitriles; Postmenopause; Premenopause; Tamoxifen; Thromboembolism; Triazoles | 2007 |
Safety of aromatase inhibitors in the adjuvant setting.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Causality; Chemotherapy, Adjuvant; Comorbidity; Estrogen Receptor Modulators; Female; Hot Flashes; Humans; Incidence; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Nitriles; Osteoporosis; Rats; Survival Analysis; Tamoxifen; Triazoles | 2007 |
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Nitriles; Postmenopause; Practice Guidelines as Topic; Quality of Life; Risk Assessment; Secondary Prevention; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Effects of hormonal therapy on cognitive functioning in breast cancer patients: a review of the literature.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cognition; Female; Gonadotropin-Releasing Hormone; Humans; Neuropsychological Tests; Nitriles; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2007 |
Effectively nursing patients receiving aromatase inhibitor therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Arthralgia; Atrophy; Breast Neoplasms; Cardiovascular Diseases; Comorbidity; Female; Hot Flashes; Humans; Lubricants; Neoplasm Recurrence, Local; Nitriles; Patient Education as Topic; Quality of Life; Tamoxifen; Triazoles; Vagina; Weight Gain | 2008 |
Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2008 |
The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Evidence-Based Medicine; Letrozole; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Quality of Life; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2008 |
The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Nurse Clinicians; Nurse Practitioners; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Postmenopause; Receptors, Estrogen; Risk Factors; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2008 |
Neoadjuvant endocrine therapy for breast cancer: past, present and future.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Forecasting; Humans; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Patient Selection; Postmenopause; Tamoxifen; Triazoles | 2008 |
Targeting breast cancer with hormonal treatment options.
Topics: Aftercare; Ambulatory Care; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor Modulators; Humans; Information Services; Internet; Letrozole; Nitriles; Nurse Practitioners; Patient Selection; Postmenopause; Practice Guidelines as Topic; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
The emerging role of aromatase inhibitors in the adjuvant management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Therapy, Combination; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
[Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Humans; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Review of the ATAC study: tamoxifen versus anastrozole in early-stage breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Early Diagnosis; Humans; Nitriles; Tamoxifen; Triazoles | 2008 |
[Adjuvant breast cancer treatment with hormono-radiotherapy].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2009 |
Breast cancer chemoprevention - a vision not yet realized.
Topics: Anastrozole; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Quality of Life; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Triazoles | 2009 |
Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Secondary Prevention; Survival Analysis; Tamoxifen; Triazoles; Women's Health | 2009 |
Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Celecoxib; Estrogens; Female; Humans; Letrozole; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Pyrazoles; Randomized Controlled Trials as Topic; Recurrence; Salvage Therapy; Sulfonamides; Tamoxifen; Triazoles | 2010 |
Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Cytochrome P-450 CYP2D6; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Genotype; Humans; Neoadjuvant Therapy; Nitriles; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2009 |
Adjuvant endocrine therapy for early breast cancer: the story so far.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2010 |
Question 2. Which medications effectively reduce pubertal gynaecomastia?
Topics: Anastrozole; Aromatase Inhibitors; Child; Estrogen Antagonists; Evidence-Based Medicine; Gynecomastia; Humans; Male; Nitriles; Puberty; Tamoxifen; Treatment Outcome; Triazoles | 2010 |
Anastrozole.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Antagonists; Female; Humans; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Time Factors; Triazoles | 2010 |
Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Colorectal Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Osteoporosis; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; RANK Ligand; Secondary Prevention; Tamoxifen; Triazoles; Zoledronic Acid | 2010 |
When to start an aromatase inhibitor: now or later?
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2011 |
Overview of adjuvant trials of aromatase inhibitors in early breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2011 |
Preventive therapy for breast cancer: a consensus statement.
Topics: Anastrozole; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Consensus Development Conferences as Topic; Diphosphonates; Estrogen Receptor Modulators; Expert Testimony; Female; Fenretinide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metformin; Nitriles; Norpregnenes; Piperidines; Premenopause; Pyrrolidines; Raloxifene Hydrochloride; Retinoids; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Triazoles | 2011 |
Update on adjuvant hormonal treatment of early breast cancer.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2011 |
Initialization of adjuvant hormonal treatment for breast cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Early Detection of Cancer; Female; Humans; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Premenopause; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Reviewing the cost-effectiveness of endocrine early breast cancer therapies: influence of differences in modeling methods on outcomes.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Models, Economic; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Tamoxifen; Time Factors; Triazoles | 2012 |
Soy products in the management of breast cancer.
Topics: Anastrozole; Animals; Aryl Hydrocarbon Hydroxylases; Asian People; Breast Neoplasms; Cytochrome P-450 CYP1B1; Diet; Drug Interactions; Female; Humans; Incidence; Isoflavones; Meta-Analysis as Topic; Nitriles; Polymorphism, Genetic; Prognosis; Proto-Oncogene Proteins c-mdm2; Receptor, ErbB-2; Recurrence; Risk Factors; Soy Foods; Tamoxifen; Triazoles | 2012 |
Pharmacogenomics of endocrine therapy in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Genome-Wide Association Study; Humans; Japan; Letrozole; Musculoskeletal Physiological Phenomena; Nitriles; Pharmacogenetics; Phenotype; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2013 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2014 |
Current concepts in breast cancer chemoprevention.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Estrogen Antagonists; Estrogens; Female; Humans; Incidence; Nitriles; Postmenopause; Premenopause; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2014 |
Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Genetic Markers; Humans; Nitriles; Predictive Value of Tests; Prognosis; Receptors, Estrogen; Reproducibility of Results; Tamoxifen; Treatment Outcome; Triazoles; Validation Studies as Topic | 2014 |
Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Neoplasm Metastasis; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2014 |
Ductal Carcinoma In Situ: Treatment Update and Current Trends.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Mammography; Mastectomy, Segmental; Neoplasm Recurrence, Local; Nitriles; Practice Guidelines as Topic; Precision Medicine; Prognosis; Radiotherapy, Adjuvant; Tamoxifen; Triazoles | 2015 |
[Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Genetic Predisposition to Disease; Humans; Mastectomy; Mutation; Nitriles; Prophylactic Surgical Procedures; Raloxifene Hydrochloride; Tamoxifen; Triazoles | 2016 |
Unravelling exemestane: From biology to clinical prospects.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Apoptosis; Aromatase Inhibitors; Autophagy; Biotransformation; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2016 |
Endocrine therapy for hormone treatment-naïve advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2016 |
Extended Adjuvant Endocrine Therapy in Breast Cancer: Evidence and Update - A Review.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2017 |
ADJUVANT (HORMONAL) THERAPY AS A CAUSE OF BONE LOSS IN PATIENTS WITH BREAST CANCER (REVIEW OF LITERATURE).
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Letrozole; Nitriles; Osteoporosis; Postmenopause; Premenopause; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2017 |
A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Randomized Controlled Trials as Topic; Recurrence; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2017 |
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Drug Substitution; Female; Humans; Mastectomy; Middle Aged; Multicenter Studies as Topic; Nitriles; Prospective Studies; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2017 |
Use of anastrozole in the chemoprevention and treatment of breast cancer: A literature review.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Chemotherapy, Adjuvant; Female; Humans; Nitriles; Postmenopause; Reproducibility of Results; Tamoxifen; Treatment Outcome; Triazoles | 2017 |
Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasms, Hormone-Dependent; Network Meta-Analysis; Nitriles; Receptor, ErbB-2; Tamoxifen; Triazoles | 2017 |
Personalized prevention in high risk individuals: Managing hormones and beyond.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Early Detection of Cancer; Female; Genes, BRCA1; Genes, BRCA2; Humans; Mammography; Middle Aged; Nitriles; Precision Medicine; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Tamoxifen; Triazoles | 2018 |
Endocrine Therapy for Ductal Carcinoma In Situ (DCIS) of the Breast with Breast Conserving Surgery (BCS) and Radiotherapy (RT): a Meta-Analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Combined Modality Therapy; Female; Humans; Incidence; Mastectomy, Segmental; Neoplasm Recurrence, Local; Radiotherapy; Tamoxifen | 2020 |
Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Humans; Letrozole; Lipids; Network Meta-Analysis; Research Design; Tamoxifen; Toremifene | 2020 |
[Endocrine adjuvant treatment specific features for young breast cancer women].
Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Goserelin; Humans; Luteolytic Agents; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Triptorelin Pamoate | 2019 |
Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer : Statement from the DEGRO working group prostate cancer.
Topics: Adenocarcinoma; Anastrozole; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Dizziness; Dose Fractionation, Radiation; Drug Administration Schedule; Estrogen Receptor Modulators; Flushing; Gynecomastia; Humans; Male; Mastodynia; Meta-Analysis as Topic; Neoplasms, Hormone-Dependent; Nitriles; Off-Label Use; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tamoxifen; Tosyl Compounds | 2020 |
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
Topics: Aminopyridines; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Trastuzumab | 2021 |
Preventing Breast Cancer Through Identification and Pharmacologic Management of High-Risk Patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Curriculum; Decision Making, Shared; Education, Medical, Continuing; Estrogen Antagonists; Female; Health Personnel; Humans; Male; Middle Aged; Preventive Medicine; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; United States | 2021 |
Health-related quality of life of women with breast cancer being treated with hormone therapy: A scoping review.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Hormones; Humans; Quality of Life; Tamoxifen | 2023 |
133 trial(s) available for anastrozole and tamoxifen
| Article | Year |
|---|---|
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Female; Humans; Megestrol; Megestrol Acetate; Middle Aged; Nitriles; Postmenopause; Prognosis; Survival Rate; Tamoxifen; Triazoles | 1996 |
The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Estrogens; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 1999 |
Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2000 |
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Estrogen Receptor Modulators; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2000 |
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Estrogen Receptor Modulators; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2000 |
[Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2001 |
Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Middle Aged; Nitriles; Postmenopause; Safety; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Female; Hemorrhage; Humans; Middle Aged; Nitriles; Postmenopause; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Tamoxifen; Thromboembolism; Treatment Outcome; Triazoles | 2001 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Endpoint Determination; Enzyme Inhibitors; Female; Humans; Middle Aged; Nitriles; Postmenopause; Prognosis; Tamoxifen; Triazoles | 2002 |
The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal patients: factors influencing the success of patient recruitment.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Humans; Nitriles; Patient Selection; Postmenopause; Surveys and Questionnaires; Tamoxifen; Triazoles | 2002 |
Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.
Topics: Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Time Factors; Treatment Outcome; Triazoles; United States | 2003 |
Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Remission Induction; Survival Analysis; Tamoxifen; Triazoles | 2003 |
Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women?
Topics: Adult; Aged; Anastrozole; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update ana
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
Advanced breast cancer updates on anastrozole versus tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Protocols; Double-Blind Method; Female; Humans; Hysteroscopy; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2003 |
Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study.
Topics: Affect; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Breast Neoplasms; Cognition Disorders; Depression; England; Estrogens; Female; Humans; Memory Disorders; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Nitriles; Personality Inventory; Pilot Projects; Reaction Time; Self-Assessment; Tamoxifen; Triazoles; Verbal Learning | 2004 |
Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Estradiol; Female; Goserelin; Humans; Injections, Subcutaneous; Middle Aged; Nitriles; Premenopause; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Over Studies; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Survival Rate; Switzerland; Tamoxifen; Triazoles | 2004 |
Breast surgery in the 'Arimidex, Tamoxifen Alone or in Combination' (ATAC) trial: American women are more likely than women from the United Kingdom to undergo mastectomy.
Topics: Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Chemotherapy, Adjuvant; Decision Making; Female; Humans; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Odds Ratio; Postmenopause; Risk Factors; Tamoxifen; Triazoles; United Kingdom; United States | 2004 |
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Enzyme Inhibitors; Evidence-Based Medicine; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Tamoxifen; Triazoles | 2004 |
Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
Topics: Anastrozole; Aromatase Inhibitors; Belgium; Body Mass Index; Breast Neoplasms; Data Interpretation, Statistical; Demography; Dyspareunia; Female; Hot Flashes; Humans; Letrozole; Logistic Models; Memory Disorders; Menopause; Middle Aged; Musculoskeletal Diseases; Nitriles; Pain; Patient Selection; Prospective Studies; Randomized Controlled Trials as Topic; Surveys and Questionnaires; Tamoxifen; Time Factors; Triazoles; Urination Disorders; Vaginal Diseases; Withholding Treatment | 2004 |
The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Protocols; Double-Blind Method; Endometrium; Female; Humans; Hysteroscopy; Nitriles; Sensitivity and Specificity; Tamoxifen; Triazoles; Ultrasonography | 2005 |
Molecular markers in the endometrium at baseline of postmenopausal patients with early breast cancer in the ATAC (Arimidex, tamoxifen, alone, or in combination) trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Needle; Breast Neoplasms; Combined Modality Therapy; Endometrium; Female; Humans; Immunohistochemistry; Mastectomy; Middle Aged; Nitriles; Postmenopause; Prognosis; Proto-Oncogene Proteins c-bcl-2; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Biomarker investigations from the ATAC trial: the role of TA01.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Neoplasm Recurrence, Local; Nitriles; Oligonucleotide Array Sequence Analysis; Patient Care Planning; Prognosis; Tamoxifen; Triazoles | 2004 |
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Anilides; Breast Diseases; Double-Blind Method; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Pain; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Tamoxifen; Testosterone; Tosyl Compounds; Triazoles | 2005 |
Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole.
Topics: Aged; Aged, 80 and over; Anastrozole; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Diseases; Double-Blind Method; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Pain; Placebos; Prostatic Neoplasms; Tamoxifen; Testosterone; Tosyl Compounds; Treatment Outcome; Triazoles | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Proliferation; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Double-Blind Method; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Predictive Value of Tests; Receptor, ErbB-2; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estradiol; Female; Humans; Japan; Lipids; Lipoprotein Lipase; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
[Survival of breast cancer patients treated with inhibitors of the aromatase vs tamoxifen].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Nitriles; Prospective Studies; Survival Rate; Tamoxifen; Triazoles | 2004 |
Zoledronic acid prevents cancer treatment-induced bone loss.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2005 |
Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chromatography, High Pressure Liquid; Double-Blind Method; Drug Interactions; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Pain; Prostatic Neoplasms; Tamoxifen; Tosyl Compounds; Triazoles | 2005 |
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Neoadjuvant Therapy; Nitriles; Odds Ratio; Placebos; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Nitriles; Postmenopause; Prospective Studies; Survival Analysis; Tamoxifen; Triazoles | 2005 |
Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers; Bone Resorption; Breast Neoplasms; Double-Blind Method; Estradiol; Female; Humans; Lipids; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status?
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Receptor, ErbB-2; Reference Values; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Endometrial Neoplasms; Endometrium; Female; Humans; Middle Aged; Nitriles; Polyps; Risk Factors; Tamoxifen; Triazoles | 2006 |
Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2005 |
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Female; Humans; In Situ Nick-End Labeling; Ki-67 Antigen; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Prognosis; Tamoxifen; Triazoles | 2006 |
Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2006 |
Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dilatation and Curettage; Endometrium; Female; Humans; Hysteroscopy; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles; Ultrasonography; Uterine Hemorrhage | 2006 |
Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
Topics: Aged; Anastrozole; Breast Neoplasms; Confidence Intervals; Cross-Sectional Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Logistic Models; Mastectomy; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Odds Ratio; Postmenopause; Preoperative Care; Receptors, Estrogen; Reference Values; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Nitriles; Postmenopause; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2006 |
Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers; Bone Density; Bone Remodeling; Breast Neoplasms; Female; Fractures, Bone; Hip; Humans; Lumbar Vertebrae; Middle Aged; Nitriles; Postmenopause; Radiography; Risk; Tamoxifen; Triazoles | 2006 |
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Therapy, Combination; Drug Tolerance; Female; Follow-Up Studies; Humans; Middle Aged; Nitriles; Postmenopause; Risk Assessment; Tamoxifen; Triazoles | 2006 |
Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Follow-Up Studies; Health Status; Humans; Nitriles; Odds Ratio; Patient Dropouts; Postmenopause; Quality of Life; Risk Assessment; Surveys and Questionnaires; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2006 |
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
Topics: Adult; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Tamoxifen; Triazoles; Zoledronic Acid | 2007 |
Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prospective Studies; Radiotherapy Dosage; Survival Rate; Tamoxifen; Triazoles | 2007 |
Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy.
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Japan; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Prospective Studies; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Nitriles; Placebos; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Nitriles; Postmenopause; Prospective Studies; Secondary Prevention; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2007 |
Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles; United Kingdom | 2007 |
Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Bone Density; Bone Remodeling; Bone Resorption; Breast Neoplasms; Estrogens; Female; Humans; Letrozole; Lipids; Menopause; Middle Aged; Nitriles; Peptide Fragments; Placebos; Procollagen; Single-Blind Method; Tamoxifen; Triazoles | 2007 |
A decade of letrozole: FACE.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Estrogen Receptor Modulators; Female; Humans; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2007 |
Switching to anastrozole after tamoxifen improves survival in postmenopausal women with breast cancer.
Topics: Aged; Anastrozole; Breast Neoplasms; Female; Humans; Nitriles; Postmenopause; Prospective Studies; Survivors; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Austria; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Lymphatic Metastasis; Male; Middle Aged; Nitriles; Odds Ratio; Postmenopause; Proportional Hazards Models; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Research Design; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2008 |
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Alkylating; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Follow-Up Studies; Fractures, Bone; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Tamoxifen; Time Factors; Triazoles | 2008 |
ERBB2 status and outcome of endocrine treatment.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; ErbB Receptors; Female; Humans; Nitriles; Postmenopause; Prognosis; Tamoxifen; Triazoles | 2008 |
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Tamoxifen; Time Factors; Tissue Array Analysis; Treatment Outcome; Triazoles | 2008 |
Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Female; Humans; Neoplasm Invasiveness; Nitriles; Postmenopause; Prospective Studies; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Over Studies; Estradiol; Estrone; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Radioimmunoassay; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Estrogen Antagonists; Female; Humans; Middle Aged; Neoadjuvant Therapy; Nitriles; Tamoxifen; Triazoles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2008 |
Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrium; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles; Ultrasonography | 2008 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Linear Models; Nitriles; Osteoporosis; Premenopause; Prospective Studies; Tamoxifen; Triazoles; Zoledronic Acid | 2008 |
Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS).
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Australia; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Decision Support Techniques; Feedback; Female; Health Knowledge, Attitudes, Practice; Humans; Informed Consent; Middle Aged; Nitriles; Patient Education as Topic; Patient Selection; Pilot Projects; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; Teaching Materials; Triazoles | 2008 |
Comparing the cost of adjuvant anastrozole with the benefits of managing less patients with relapsed breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles; United Kingdom | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Estrogen Antagonists; Female; Follow-Up Studies; Goserelin; Humans; Imidazoles; Middle Aged; Nitriles; Premenopause; Receptors, Estrogen; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biopsy, Needle; Breast Neoplasms; Disease-Free Survival; Female; Gene Expression Profiling; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Predictive Value of Tests; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2009 |
Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carpal Tunnel Syndrome; Chemotherapy, Adjuvant; Double-Blind Method; Female; Humans; Middle Aged; Nitriles; Postmenopause; Risk Factors; Tamoxifen; Triazoles | 2009 |
Comparison of the effect of the aromatase inhibitor, anastrazole, to the antioestrogen, tamoxifen citrate, on canine prostate and semen.
Topics: Anastrozole; Animals; Aromatase Inhibitors; Dog Diseases; Dogs; Estrogen Antagonists; Male; Nitriles; Prostate; Prostatic Hyperplasia; Semen; Tamoxifen; Triazoles | 2009 |
[Safety and compliance with UFT (tegafur and uracil) alone and in combination with hormone therapy in patients with breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Patient Compliance; Postmenopause; Tamoxifen; Tegafur; Triazoles; Uracil | 2009 |
Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast; Breast Neoplasms; Cytochrome P-450 CYP2D6; Disease-Free Survival; Female; Genotype; Humans; Nitriles; Pharmacogenetics; Precancerous Conditions; Risk; Tamoxifen; Treatment Outcome; Triazoles | 2009 |
A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Bone and Bones; Bone Resorption; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2010 |
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Genetic Testing; Humans; Lymph Nodes; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Risk Factors; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2010 |
Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Computer Simulation; Cost-Benefit Analysis; Female; Germany; Health Care Costs; Humans; Incidence; Middle Aged; Models, Economic; Nitriles; Tamoxifen; Triazoles | 2010 |
Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Japan; Kaplan-Meier Estimate; Neoplasm Staging; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2010 |
Adding zoledronic acid to endocrine therapy in the adjuvant treatment of hormone-sensitive breast cancer in premenopausal women: a new care standard or a provocative idea?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Neoplasms, Hormone-Dependent; Nitriles; Premenopause; Prognosis; Survival Rate; Tamoxifen; Triazoles; Zoledronic Acid | 2010 |
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Double-Blind Method; Estrogen Antagonists; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2010 |
The ATAC adjuvant breast-cancer trial: six-year results of the endometrial subprotocol.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Endometrium; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2010 |
Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Over Studies; Endocrine System; Humans; Letrozole; Middle Aged; Nitriles; Quality of Life; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Nitriles; Postmenopause; Quality of Life; Sexual Dysfunction, Physiological; Tamoxifen; Treatment Outcome; Triazoles; Uterus | 2011 |
Short-term anastrozole therapy reduces Ki-67 and progesterone receptor expression in invasive breast cancer: a prospective, placebo-controlled, double-blind trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Middle Aged; Nitriles; Prospective Studies; Receptors, Progesterone; Tamoxifen; Triazoles | 2011 |
Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Resorption; Breast Neoplasms; Female; Hip; Humans; Lumbar Vertebrae; Nitriles; Tamoxifen; Time; Triazoles | 2011 |
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Topics: Administration, Oral; Anastrozole; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Neoplasm Staging; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2010 |
The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Japan; Lipids; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles; Triglycerides | 2011 |
Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1-4 years: N-SAS BC 03.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Quality of Life; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Bone and Bones; Bone Density; Bone Resorption; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2010 |
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Female; Goserelin; Humans; Middle Aged; Nitriles; Premenopause; Prospective Studies; Recurrence; Retrospective Studies; Risk; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imidazoles; Middle Aged; Neoplasm Staging; Nitriles; Premenopause; Tamoxifen; Treatment Outcome; Triazoles; Zoledronic Acid | 2011 |
Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial.
Topics: Adult; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Comorbidity; Double-Blind Method; Female; Humans; Middle Aged; Nitriles; Retrospective Studies; Risk; Tamoxifen; Triazoles | 2011 |
Outcomes of Japanese breast cancer patients treated with pre-operative and post-operative anastrozole or tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Asian People; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Nitriles; Postoperative Period; Tamoxifen; Triazoles | 2012 |
Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Data Mining; Female; Genome-Wide Association Study; Genome, Human; Humans; Linkage Disequilibrium; Models, Genetic; Nitriles; Polymorphism, Single Nucleotide; Raloxifene Hydrochloride; Software; Tamoxifen; Triazoles | 2012 |
Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Depression; Female; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Stress, Psychological; Surveys and Questionnaires; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Goserelin; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Premenopause; Receptor, ErbB-2; Tamoxifen; Triazoles | 2012 |
Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Austria; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prospective Studies; Survival Rate; Tamoxifen; Triazoles | 2012 |
Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin D1; Female; Follow-Up Studies; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Predictive Value of Tests; Prognosis; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Goserelin; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Nitriles; Predictive Value of Tests; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen Anastrozole trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Endometrial Neoplasms; Female; Follow-Up Studies; Fractures, Bone; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Risk Factors; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2013 |
Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Gonadotropin-Releasing Hormone; Goserelin; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2013 |
Predictors of recovery of ovarian function during aromatase inhibitor therapy.
Topics: Adult; Amenorrhea; Anastrozole; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Estradiol; Female; Humans; Middle Aged; Nitriles; Ovary; Primary Ovarian Insufficiency; Prospective Studies; Receptors, Estrogen; Tamoxifen; Triazoles; Uterine Hemorrhage | 2013 |
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Prognosis; Prospective Studies; Receptors, Estrogen; Tamoxifen; Triazoles | 2013 |
Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Pilot randomised study of early intervention based on tumour markers in the follow-up of patients with primary breast cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoembryonic Antigen; Early Detection of Cancer; Female; Follow-Up Studies; Goserelin; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Mucin-1; Nitriles; Pilot Projects; Single-Blind Method; Tamoxifen; Treatment Outcome; Triazoles | 2014 |
A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer.
Topics: Aged; Anastrozole; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Fatty Liver; Female; Humans; Liver; Middle Aged; Nitriles; Prospective Studies; Tamoxifen; Treatment Failure; Triazoles | 2014 |
Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tamoxifen; Triazoles | 2014 |
Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Austria; Breast Neoplasms; Data Interpretation, Statistical; Female; Follow-Up Studies; Hormones; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Prognosis; Proportional Hazards Models; Regression Analysis; Risk; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2015 |
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Follow-Up Studies; Goserelin; Humans; Imidazoles; Kaplan-Meier Estimate; Middle Aged; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2015 |
Does patient education work in breast cancer? Final results from the global CARIATIDE study.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Patient Compliance; Patient Education as Topic; Tamoxifen; Triazoles | 2015 |
A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cognition Disorders; Female; Humans; Letrozole; Memory; Middle Aged; Nitriles; Postmenopause; Psychomotor Performance; Quality of Life; Tamoxifen; Triazoles | 2015 |
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2016 |
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Topics: Administration, Oral; Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Double-Blind Method; Embolism; Female; Humans; Mastectomy, Segmental; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Thrombosis; Triazoles | 2016 |
Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Double-Blind Method; Female; Follow-Up Studies; Humans; Mastectomy, Segmental; Middle Aged; Nitriles; Postmenopause; Quality of Life; Tamoxifen; Triazoles | 2016 |
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clinical Decision-Making; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Gene Expression Profiling; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Letrozole; Mastectomy, Segmental; Middle Aged; Molecular Typing; Neoadjuvant Therapy; Nitriles; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Registries; Tamoxifen; Taxoids; Treatment Outcome; Triazoles; Young Adult | 2017 |
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Mastectomy; Maximum Tolerated Dose; Middle Aged; Netherlands; Nitriles; Postmenopause; Prognosis; Prospective Studies; Receptor, ErbB-2; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2017 |
Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Double-Blind Method; Female; Humans; Medication Adherence; Middle Aged; Tamoxifen | 2018 |
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Pharmacological; Biomarkers, Tumor; Breast Neoplasms; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Recurrence, Local; Predictive Value of Tests; Prognosis; Receptor, ErbB-2; Retrospective Studies; Tamoxifen; Transcriptome; Treatment Outcome | 2018 |
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2018 |
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Models, Statistical; Neoplasm Recurrence, Local; Predictive Value of Tests; Prognosis; Receptors, Estrogen; Reproducibility of Results; Risk; Tamoxifen | 2018 |
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label,
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Goserelin; Humans; Neoplasm Metastasis; Premenopause; Tamoxifen | 2018 |
Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Letrozole; Male; Middle Aged; Neoplasm Staging; Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Tamoxifen; Treatment Outcome | 2018 |
Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Cross-Over Studies; Disease-Free Survival; Feasibility Studies; Female; Genetic Predisposition to Disease; Goserelin; Heterozygote; Humans; Mutation; Northern Ireland; Patient Acceptance of Health Care; Patient Selection; Premenopause; Prognosis; Risk Assessment; Survival Rate; Tamoxifen; Treatment Outcome; Ubiquitin-Protein Ligases | 2018 |
Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Ovary; Postmenopause; Proportional Hazards Models; Survival Rate; Tamoxifen | 2019 |
Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Breast Neoplasms; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies; Tamoxifen | 2019 |
PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial.
Topics: Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Gene Expression Profiling; Humans; Lymph Nodes; Mastectomy, Segmental; Neoplasm Grading; Neoplasm Recurrence, Local; Postmenopause; Prognosis; Radiotherapy, Adjuvant; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen | 2021 |
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
Topics: Administration, Oral; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Fractures, Bone; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2021 |
Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy.
Topics: Anastrozole; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Prognosis; Receptor, ErbB-2; Retrospective Studies; Tamoxifen | 2022 |
Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.
Topics: Adjuvants, Immunologic; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Nitriles; Prospective Studies; Tamoxifen; Triazoles | 2023 |
Racial and Ethnic Disparities in Outcomes After Breast-Conserving Therapy and Endocrine Therapy for DCIS: A Post-Hoc Analysis of the NSABP B-35 Randomized Clinical Trial.
Topics: Anastrozole; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Ethnicity; Female; Humans; Tamoxifen | 2023 |
268 other study(ies) available for anastrozole and tamoxifen
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
Topics: 17-Hydroxysteroid Dehydrogenases; Androstane-3,17-diol; Androstanes; Biocatalysis; Cell Line; Dihydrotestosterone; Enzyme Inhibitors; Estradiol; Estrone; Humans; Inhibitory Concentration 50; Oxidation-Reduction; Substrate Specificity | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
Topics: Drug Discovery; Pharmaceutical Preparations; Solubility; Thermodynamics | 2015 |
Aromatase inhibitors in metastatic breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Female; Humans; Megestrol Acetate; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Triazoles | 1996 |
Role of new selective aromatase inhibitor in therapy for metastatic breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles | 1997 |
Fetal death in mice lacking 5alpha-reductase type 1 caused by estrogen excess.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Anastrozole; Androstenedione; Animals; Biological Assay; Decidua; Dose-Response Relationship, Drug; Embryonic and Fetal Development; Estrogen Antagonists; Estrogens; Female; Fetal Death; Gene Expression Regulation, Enzymologic; In Situ Hybridization; Litter Size; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nitriles; Placenta; RNA, Messenger; Steroids; Tamoxifen; Triazoles; Uterus | 1997 |
Predictors of response to second-line endocrine therapy for breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Gonanes; Goserelin; Humans; Megestrol Acetate; Middle Aged; Nitriles; Ovariectomy; Predictive Value of Tests; Remission Induction; Tamoxifen; Triazoles | 1997 |
Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Screening Assays, Antitumor; Endometrial Neoplasms; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Neoplasms, Hormone-Dependent; Nitriles; Organ Size; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles; Tumor Cells, Cultured; Uterus | 1998 |
The effects of aromatase inhibitors and antiestrogens in the nude mouse model.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Nitriles; Tamoxifen; Triazoles; Tumor Cells, Cultured | 1998 |
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Evaluation Studies as Topic; Female; Hormone Replacement Therapy; Humans; Megestrol Acetate; Menopause; Middle Aged; Nitriles; Pilot Projects; Quality of Life; Surveys and Questionnaires; Tamoxifen; Time Factors; Triazoles | 1999 |
The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
Topics: Analysis of Variance; Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Aromatase Inhibitors; Disease Models, Animal; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Tamoxifen; Time Factors; Triazoles; Tumor Cells, Cultured | 1999 |
Safety and tolerability of endocrine therapies used in the treatment of advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Tolerance; Female; Humans; Megestrol Acetate; Nitriles; Safety; Tamoxifen; Triazoles | 1999 |
Future directions in endocrine treatment of advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Megestrol Acetate; Nitriles; Tamoxifen; Triazoles | 1999 |
Endocrine options for breast cancer treatment: looking beyond tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Goserelin; Humans; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2000 |
Clinical trials in cancer: what makes for a successful study?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Double-Blind Method; Drug Industry; Female; Humans; Interinstitutional Relations; Mastectomy; Medical Audit; Motivation; Multicenter Studies as Topic; Nitriles; Patient Selection; Patients; Physician-Patient Relations; Prospective Studies; Randomized Controlled Trials as Topic; Research Design; Tamoxifen; Triazoles | 2000 |
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Arsenic Trioxide; Arsenicals; Bexarotene; Breast Neoplasms; Drug Approval; Female; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, T-Cell, Cutaneous; Nitriles; Oxides; Paclitaxel; Tamoxifen; Tetrahydronaphthalenes; Triazoles; United States; United States Food and Drug Administration | 2001 |
The Twenty-third Annual San Antonio Breast Cancer Symposium.
Topics: Anastrozole; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Estradiol; Estrogen Antagonists; Female; Fluorouracil; Fulvestrant; Humans; Letrozole; Male; Mastectomy; Nitriles; Prognosis; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2001 |
Aromatase inhibitors and inactivators in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Estrogens; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2001 |
HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Female; Gene Amplification; Humans; Immunohistochemistry; Ki-67 Antigen; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Triazoles | 2001 |
World's largest breast cancer treatment trial supports anastrozole use.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Humans; Multicenter Studies as Topic; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2002 |
Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estrogen Receptor Modulators; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Letrozole; Menopause; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2001 |
Hormones 'R' us.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Estrogen Antagonists; Female; Humans; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2002 |
New breast cancer drugs expand treatment options.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2002 |
A better medication for treating breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2002 |
Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer.
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2002 |
Estrogen as therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase II as Topic; Diethylstilbestrol; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estrogens; Female; Humans; Letrozole; Megestrol Acetate; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Salvage Therapy; Tamoxifen; Treatment Outcome; Triazoles | 2002 |
Promising results for Arimidex and Femara.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2001 |
Stick with tried-and-true breast cancer treatment.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2002 |
Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome.
Topics: Anastrozole; Aromatase Inhibitors; Child; Enzyme Inhibitors; Estrogen Antagonists; Female; Fibrous Dysplasia, Polyostotic; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Menarche; Nitriles; Puberty, Precocious; Tamoxifen; Triazoles | 2002 |
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer: methodologic issues.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Randomized Controlled Trials as Topic; Research Design; Tamoxifen; Triazoles | 2002 |
[Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2002 |
Anastrozole versus progestins/tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Forecasting; Humans; Multicenter Studies as Topic; Nitriles; Progestins; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis; Tamoxifen; Triazoles | 2002 |
Selective oestrogen receptor downregulator.
Topics: Anastrozole; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Down-Regulation; Estradiol; Female; Fulvestrant; Humans; Nitriles; Receptors, Estrogen; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2002 |
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast carcinoma.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Female; Humans; Multicenter Studies as Topic; Nitriles; Reproducibility of Results; Research Design; Retrospective Studies; Survival; Tamoxifen; Triazoles | 2002 |
Effects of anastrozole on lipid metabolism compared with tamoxifen in rats.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Cholesterol; Drug Combinations; Enzyme Inhibitors; Female; Lipoprotein Lipase; Nitriles; Rats; Tamoxifen; Triazoles; Triglycerides | 2002 |
Current role of endocrine therapy in the management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estrogen Receptor Modulators; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2002 |
Has tamoxifen had its day?
Topics: Anastrozole; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2002 |
A new day dawns: women without oestrogen or is a balance best?
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2002 |
Advances in breast oncology: the 2002 ASCO meeting.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclooxygenase Inhibitors; Docetaxel; Evidence-Based Medicine; Female; Humans; Nitriles; Paclitaxel; Sentinel Lymph Node Biopsy; Tamoxifen; Taxoids; Technology Assessment, Biomedical; Triazoles | 2002 |
New treatment option for postmenopausal women with early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Approval; Enzyme Inhibitors; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2002 |
[Summit meeting of breast cancer experts--many new ideas and practical progress. When the breast becomes malignant].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Mammography; Mass Screening; Nitriles; Quality Assurance, Health Care; Tamoxifen; Triazoles | 2003 |
Update on ATAC.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2003 |
Anastrozole (Arimidex) vs. tamoxifen for treatment of early breast cancer.
Topics: Anastrozole; Asthenia; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Estrogen Antagonists; Fees, Pharmaceutical; Female; Headache; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2003 |
Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Canada; Cost-Benefit Analysis; Decision Support Techniques; Enzyme Inhibitors; Humans; Letrozole; Meta-Analysis as Topic; Nitriles; Quality of Life; Tamoxifen; Triazoles | 2003 |
ATAC trial: reporting interim results is not helpful.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2003 |
Breast cancer prevention.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Utilization; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2003 |
[Hormone therapy, chemotherapy and immunotherapy in breast carcinoma. The best strategy for your patient].
Topics: Adult; Age Factors; Aged; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Immunotherapy; Letrozole; Meta-Analysis as Topic; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Premenopause; Prognosis; Quality of Health Care; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Toremifene; Trastuzumab; Triazoles | 2003 |
Examining quality of life issues in relation to endocrine therapy for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Decision Making; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Nitriles; Quality of Life; Tamoxifen; Triazoles | 2003 |
Future directions in the endocrine therapy of breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Endocrine System; Estradiol; Female; Fulvestrant; Humans; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
Adjuvant aromatase inhibitors: are we there yet?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Enzyme Inhibitors; Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Triazoles | 2003 |
ATAC trial did not report interim results.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2003 |
The effects of hormone therapy on cognition in breast cancer.
Topics: Affect; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cognition; Cognition Disorders; Enzyme Inhibitors; Female; Humans; Memory; Middle Aged; Nitriles; Pilot Projects; Psychometrics; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2003 |
Hormonal therapy: introduction.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Letrozole; Nitriles; Prognosis; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles; United Kingdom | 2003 |
Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Health Care Costs; Health Services; Humans; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Triazoles | 2003 |
Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Enzyme Inhibitors; Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Time Factors; Triazoles | 2004 |
Prevention strategies with aromatase inhibitors.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Cyclooxygenase 2; Dinoprostone; Enzyme Inhibitors; Female; Humans; Isoenzymes; Membrane Proteins; Models, Biological; Neoplasms; Nitriles; Placebos; Postmenopause; Prostaglandin-Endoperoxide Synthases; Receptors, Estrogen; Tamoxifen; Time Factors; Triazoles | 2004 |
Feasibility of sentinel node biopsy for breast cancer after neoadjuvant endocrine therapy: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Anthracyclines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Bridged-Ring Compounds; Feasibility Studies; Female; Goserelin; Humans; Lymph Nodes; Middle Aged; Neoadjuvant Therapy; Nitriles; Pilot Projects; Sentinel Lymph Node Biopsy; Tamoxifen; Taxoids; Triazoles | 2004 |
[New prevention strategies against breast cancer and cervical carcinoma. What can you advice to your patients].
Topics: Adolescent; Adult; Age Factors; Anastrozole; Anticarcinogenic Agents; Breast Neoplasms; Celecoxib; Child; Double-Blind Method; Estrogen Antagonists; Female; Germany; Hormone Replacement Therapy; Humans; Hysterectomy; Life Style; Mammography; Menarche; Menopause; Middle Aged; Nitriles; Ovariectomy; Pregnancy; Pyrazoles; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Smoking; Sulfonamides; Tamoxifen; Triazoles; Uterine Cervical Neoplasms | 2003 |
[Interview with Prof. Dr. Wolfgang Eiermann. Which women need a medicamentous breast cancer prophylaxis?].
Topics: Age Factors; Anastrozole; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Life Style; Mammography; Middle Aged; Nitriles; Quality of Life; Risk Assessment; Risk Factors; Tamoxifen; Triazoles | 2003 |
[The uterine sarcoma, a new risk identified for tamoxifen].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinosarcoma; Enzyme Inhibitors; Estrogen Receptor Modulators; Female; Humans; Metrorrhagia; Middle Aged; Neoplasms, Second Primary; Nitriles; Risk; Tamoxifen; Triazoles; Uterine Neoplasms | 2004 |
Comment on "Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results" by J.-M. Nabholtz et al.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Letrozole; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Triazoles | 2004 |
Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy.
Topics: Adult; Aged; Anastrozole; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Letrozole; Magnetic Resonance Imaging; Middle Aged; Nitriles; Pamidronate; Pilot Projects; Prospective Studies; Tamoxifen; Triazoles; Zoledronic Acid | 2004 |
Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Middle Aged; Models, Theoretical; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Nitriles; Odds Ratio; Postmenopause; Quality of Life; Surveys and Questionnaires; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Budgets; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Female; Humans; Italy; Letrozole; Markov Chains; Megestrol; Models, Economic; National Health Programs; Nitriles; Postmenopause; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |
Oestrogen-selective modulation of FSH and LH secretion by pituitary gland.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogens; Female; Follicle Stimulating Hormone; Goserelin; Humans; Luteinizing Hormone; Nitriles; Pituitary Gland; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2005 |
How rapidly do oncologists respond to clinical trial data?
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Evidence-Based Medicine; Female; Health Care Surveys; Humans; Medical Oncology; Middle Aged; Nitriles; Postmenopause; Practice Patterns, Physicians'; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2005 |
Anastrozole data show continued delay in relapse, but no clear survival advantage.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles; United Kingdom | 2005 |
Expression of estrogen receptors-alpha and -beta in primary breast neoplasms and tumors exposed to neoadjuvant hormonal therapy.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Gene Expression Regulation, Neoplastic; Humans; Nitriles; Receptors, Progesterone; RNA, Messenger; Tamoxifen; Triazoles | 2004 |
[Breast carcinoma: new, much promising trends. The cancer anxiety of women -- will be taken better care soon?].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Austria; Breast Neoplasms; Clinical Trials as Topic; Female; Fractures, Bone; Germany; Humans; Mammography; Middle Aged; Multicenter Studies as Topic; Nitriles; Osteoporosis; Randomized Controlled Trials as Topic; Risk; Risk Factors; Tamoxifen; Time Factors; Triazoles | 2005 |
[New strategies against breast carcinoma. To outwit the resistance tendency of tumor cells].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Time Factors; Triazoles | 2005 |
Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Nitriles; Oligonucleotide Array Sequence Analysis; Tamoxifen; Triazoles; Up-Regulation | 2005 |
Selected highlights from the 27th San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004.
Topics: Anastrozole; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Delivery Systems; Drug Therapy, Combination; Estradiol; Female; Fulvestrant; Gonadal Steroid Hormones; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2005 |
Aromatase inhibitors: cellular and molecular effects.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Nitriles; Oligonucleotide Array Sequence Analysis; Receptors, Progesterone; Tamoxifen; Triazoles | 2005 |
Case records of the Massachusetts General Hospital. Case 24-2005. A 58-year-old woman with early-stage estrogen-receptor-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Diagnosis, Differential; Female; Humans; Mammography; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Nitriles; Radiotherapy, Adjuvant; Receptors, Estrogen; Sentinel Lymph Node Biopsy; Tamoxifen; Triazoles | 2005 |
Radiotherapeutic prophylaxis of gynecomastia.
Topics: Anastrozole; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Gynecomastia; Humans; Male; Nitriles; Pain; Prostatic Neoplasms; Quality of Life; Tamoxifen; Tosyl Compounds; Triazoles | 2005 |
Regression of tamoxifen-stimulated massive uterine fibroid after conversion to anastrozole.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Female; Humans; Leiomyoma; Nitriles; Remission Induction; Retreatment; Tamoxifen; Triazoles; Ultrasonography; Uterine Neoplasms | 2005 |
Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Estrogen Antagonists; Humans; Inhibitory Concentration 50; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Tamoxifen; Time Factors; Triazoles | 2005 |
Case 24-2005: a woman with estrogen-receptor-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fractures, Bone; Humans; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2005 |
Treatment guidelines for adjuvant breast cancer are moving toward double standards: one for the rich and one for the poor.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Decision Making; Developing Countries; Disease-Free Survival; Drug Costs; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2005 |
Improvement in dermatomyositis rash associated with the use of antiestrogen medication.
Topics: Adult; Anastrozole; Biopsy; Breast Neoplasms; Dermatomyositis; Diagnosis, Differential; Estrogen Antagonists; Exanthema; Female; Follow-Up Studies; Glucocorticoids; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Skin; Tamoxifen; Triazoles | 2006 |
Anastrozole called breast cancer "lifesaver". Recipients showed a 40 percent decrease in relapse risk when switched to anastrazole after tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2005 |
Changing the gold standard in adjuvant therapy for breast cancer:from tamoxifen to aromatase inhibition.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2005 |
Does survival increase in metastatic breast cancer with recently available anticancer drugs?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Retrospective Studies; Survival Analysis; Tamoxifen; Triazoles | 2006 |
Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.
Topics: Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Sensitivity and Specificity; Survival Rate; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2006 |
[Advances in the treatment of breast carcinoma. New therapy schedules with astonishing success quotas].
Topics: Age Factors; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Docetaxel; Female; Humans; Mammography; Meta-Analysis as Topic; Middle Aged; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Risk; Tamoxifen; Taxoids; Time Factors; Trastuzumab; Triazoles | 2006 |
Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Renal Dialysis; Tamoxifen; Triazoles | 2006 |
Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.
Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Receptor Modulators; Female; Follicle Stimulating Hormone; Humans; Letrozole; Luteinizing Hormone; Middle Aged; Neoplasm Staging; Nitriles; Ovariectomy; Practice Guidelines as Topic; Tamoxifen; Triazoles | 2006 |
Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Computer Simulation; Cost-Benefit Analysis; Estrogen Antagonists; Estrogens; Fees, Pharmaceutical; Female; Follow-Up Studies; Humans; Letrozole; Markov Chains; Middle Aged; Models, Theoretical; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2006 |
Estrogen receptors: role in breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Gene Expression Regulation, Neoplastic; Gonadotropin-Releasing Hormone; Hormone Replacement Therapy; Humans; Letrozole; Models, Biological; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2006 |
Management of choroidal metastases from breast carcinomas using aromatase inhibitors.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Choroid Neoplasms; Combined Modality Therapy; Female; Humans; Letrozole; Mastectomy, Radical; Mastectomy, Segmental; Mastectomy, Simple; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Nitriles; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Drug Administration Schedule; Drug Costs; Female; Humans; Markov Chains; Middle Aged; Models, Economic; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Treatment Outcome; Triazoles; United States | 2007 |
Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cost-Benefit Analysis; Decision Trees; Disease-Free Survival; Economics, Pharmaceutical; Humans; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Slovenia; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Receptors, Estrogen; Receptors, Progesterone; Sensitivity and Specificity; Survival Rate; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2006 |
Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost of Illness; Cost-Benefit Analysis; Drug Costs; Female; Humans; Markov Chains; Middle Aged; Models, Economic; Nitriles; Postmenopause; Quality of Life; Quality-Adjusted Life Years; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Capecitabine; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Lobular; Carcinoma, Signet Ring Cell; Deoxycytidine; Estradiol; Facial Neoplasms; Female; Fluorouracil; Fulvestrant; Humans; Incidental Findings; Letrozole; Mastectomy, Radical; Megestrol Acetate; Melanoma; Neoplasms, Second Primary; Neoplastic Cells, Circulating; Nitriles; Selective Estrogen Receptor Modulators; Skin Neoplasms; Tamoxifen; Triazoles; Wound Healing | 2006 |
Impact of aromatase inhibitors on adhesion formation in a rat model.
Topics: Anastrozole; Animals; Aromatase Inhibitors; Cytokines; Disease Models, Animal; Female; Medroxyprogesterone Acetate; Nitriles; Postoperative Complications; Rats; Rats, Wistar; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Tissue Adhesions; Triazoles; Uterine Diseases; Uterus | 2007 |
Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Belgium; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Costs; Female; Humans; Letrozole; Markov Chains; Middle Aged; Nitriles; Postmenopause; Proportional Hazards Models; Quality-Adjusted Life Years; Tamoxifen; Triazoles | 2007 |
[Locally advanced breast cancer with a good response to sequential endocrine monotherapy--a case report].
Topics: Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Administration Schedule; Female; Humans; Nitriles; Remission Induction; Tamoxifen; Triazoles | 2007 |
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
Topics: Adult; Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptors, Estrogen; Sample Size; Tamoxifen; Triazoles | 2007 |
Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Costs; Female; Health Services Research; Humans; Markov Chains; Middle Aged; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Triazoles; United Kingdom; United States | 2007 |
Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors.
Topics: Adult; Aged; Amenorrhea; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Female; Humans; Lasers; Middle Aged; Nitriles; Ophthalmoscopy; Optic Disk; Selective Estrogen Receptor Modulators; Survival Rate; Survivors; Tamoxifen; Triazoles; Visual Acuity | 2007 |
Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Communication Barriers; Decision Making; Europe; Female; Health Knowledge, Attitudes, Practice; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Selective Estrogen Receptor Modulators; Surveys and Questionnaires; Tamoxifen; Triazoles | 2007 |
Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colles' Fracture; Female; Fractures, Bone; Humans; Middle Aged; Nitriles; Postmenopause; Risk Assessment; Tamoxifen; Triazoles; Wrist Injuries | 2007 |
Optimal use of aromatase inhibitors: to lead or to follow?
Topics: Aged; Alleles; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Recurrence; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Bone density in breast cancer: when to intervene?
Topics: Absorptiometry, Photon; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Goserelin; Humans; Imidazoles; Nitriles; Osteoporosis; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; Zoledronic Acid | 2007 |
Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Letrozole; Markov Chains; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; United Kingdom | 2008 |
Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336).
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Apoptosis; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Female; G1 Phase; Humans; In Situ Nick-End Labeling; Mice; Mice, Nude; Neoplasm Transplantation; Nitriles; Ovariectomy; Piperidines; Pyridines; S Phase; Tamoxifen; Triazoles | 2007 |
Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome.
Topics: Aged; Anastrozole; Antibodies, Antinuclear; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Receptor Modulators; Female; Humans; Middle Aged; Nitriles; Sjogren's Syndrome; Tamoxifen; Triazoles | 2007 |
Responses to concurrent radiotherapy and hormone-therapy and outcome for large breast cancers in post-menopausal women.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Combined Modality Therapy; Estrogen Antagonists; Female; Humans; Middle Aged; Nitriles; Postmenopause; Radiotherapy Dosage; Retrospective Studies; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Efficacy of anastrozole on local recurrence in patients with favorable early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Mastectomy, Segmental; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2007 |
Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Triazoles | 2008 |
Extended adjuvant therapy for breast cancer--how much is enough?
Topics: Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Austria; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Long-term outcomes of aromatase inhibition for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Female; Follow-Up Studies; Fractures, Bone; Humans; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Time Factors; Triazoles | 2008 |
Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2008 |
Inappropriate ATAC on tamoxifen.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Risk Assessment; Survival Analysis; Tamoxifen; Time Factors; Triazoles | 2008 |
Inappropriate ATAC on tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Diseases; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Retinal hemorrhages in anastrozole users.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Fluorescein Angiography; Humans; Middle Aged; Nitriles; Patient Selection; Retinal Hemorrhage; Retrospective Studies; Tamoxifen; Tomography, Optical Coherence; Triazoles | 2008 |
MCF-7aro/ERE, a novel cell line for rapid screening of aromatase inhibitors, ERalpha ligands and ERRalpha ligands.
Topics: Anastrozole; Aromatase Inhibitors; Biological Assay; Cell Line, Tumor; Coumarins; ERRalpha Estrogen-Related Receptor; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Fulvestrant; Genes, Reporter; Genistein; Humans; Letrozole; Ligands; Luciferases; Nitriles; Receptors, Estrogen; Response Elements; Tamoxifen; Thiazoles; Transfection; Triazoles | 2008 |
Cutaneous vasculitis in breast cancer treated with chemotherapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; ErbB Receptors; Female; Humans; Middle Aged; Nitriles; Paraneoplastic Syndromes; Skin Diseases, Vascular; Tamoxifen; Triazoles; Vasculitis | 2008 |
[Extended adjuvant hormone therapy (in breast cancer): Why? To whom? What? How long?].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Estrogen Receptor Modulators; Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Time Factors; Triazoles | 2008 |
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Arthritis; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Drug Interactions; Female; Humans; Joint Diseases; Likelihood Functions; Logistic Models; Middle Aged; Multivariate Analysis; Nitriles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Tamoxifen; Triazoles | 2008 |
Vitreo-retinal traction and anastrozole use.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fovea Centralis; Humans; Middle Aged; Nitriles; Tamoxifen; Tomography, Optical Coherence; Triazoles | 2009 |
Clinical trial presentations, agency guidelines, and oncology practice: findings from the arimidex, tamoxifen, alone or in combination trial.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Nitriles; Practice Guidelines as Topic; Tamoxifen; Triazoles | 2008 |
Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cytochrome P-450 CYP2D6; Estrogen Receptor Modulators; Female; Humans; Markov Chains; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2008 |
Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Asian People; Breast Neoplasms; Chemotherapy, Adjuvant; Cytochrome P-450 CYP2D6; Decision Making; Disease-Free Survival; Estrogen Receptor Modulators; Female; Genotype; Humans; Markov Chains; Middle Aged; Nitriles; Patient Participation; Postmenopause; Tamoxifen; Triazoles | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptors, Estrogen; Reproducibility of Results; Risk Assessment; Risk Factors; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Biomarkers, Tumor; Breast Neoplasms; Female; Hot Flashes; Humans; Joints; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Odds Ratio; Postmenopause; Predictive Value of Tests; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Tamoxifen; Treatment Outcome; Triazoles; Vasomotor System | 2008 |
A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Genital Diseases, Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Retrospective Studies; Tamoxifen; Triazoles | 2009 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Disorders; Female; Follow-Up Studies; Humans; Mental Recall; Middle Aged; Neoplasms, Hormone-Dependent; Neuropsychological Tests; Nitriles; Prospective Studies; Psychometrics; Reaction Time; Receptors, Estrogen; Tamoxifen; Triazoles | 2009 |
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Nitriles; Patient Compliance; Postmenopause; Tamoxifen; Triazoles | 2009 |
Mean platelet volume increase after tamoxifen, but not after anastrazole in adjuvant therapy of breast cancer.
Topics: Adult; Aged; Anastrozole; Blood Platelets; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Nitriles; Platelet Count; Retrospective Studies; Tamoxifen; Triazoles | 2010 |
Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoplasm Staging; Nitriles; Retrospective Studies; Tamoxifen; Treatment Outcome; Triazoles | 2009 |
[Nineteen years postoperatively, anastrozole, UFT and cyclophosphamide combination therapy remained effective against recurrent hormone responsive breast cancer with intraabdominal lymphnode, pleural, skin and bone metastases in old age following sixteen-
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Female; Hormone Replacement Therapy; Humans; Lymphatic Metastasis; Nitriles; Pleural Neoplasms; Radiography; Recurrence; Skin Neoplasms; Tamoxifen; Tegafur; Time Factors; Triazoles; Uracil | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Data Interpretation, Statistical; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Therapy, Combination; Female; Goserelin; Humans; Nitriles; Premenopause; Tamoxifen; Triazoles | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Confidence Intervals; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Receptor, ErbB-2; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2009 |
Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
Topics: Anastrozole; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Humans; Letrozole; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Triazoles; Tumor Cells, Cultured | 2009 |
NCCN Guideline update: Breast Cancer Version 1.2004.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Combined Modality Therapy; Female; Humans; Letrozole; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2004 |
Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Letrozole; Nitriles; Pharmacogenetics; Receptors, Estrogen; Tamoxifen; Triazoles | 2010 |
Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2010 |
ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin-1; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Nitriles; Pyrrolidines; Receptor, Endothelin A; Tamoxifen; Time Factors; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Role of testosterone/estradiol ratio in predicting the efficacy of tamoxifen citrate treatment in idiopathic oligoasthenoteratozoospermic men.
Topics: Adult; Anastrozole; Aromatase Inhibitors; Estradiol; Humans; Male; Nitriles; Oligospermia; Predictive Value of Tests; Sperm Motility; Spermatozoa; Tamoxifen; Testosterone; Triazoles | 2009 |
Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors.
Topics: Anastrozole; Anesthetics, Combined; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Early Detection of Cancer; Female; Gonadal Steroid Hormones; Humans; Immunohistochemistry; Neoplasm Recurrence, Local; Nitriles; Practice Guidelines as Topic; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Triazoles | 2010 |
Endocrine therapy is associated with low performance on some estrogen-sensitive cognitive tasks in postmenopausal women with breast cancer.
Topics: Aged; Anastrozole; Breast Neoplasms; Case-Control Studies; Cognition Disorders; Estrogen Antagonists; Fatigue; Female; Humans; Memory Disorders; Middle Aged; Mood Disorders; Neuropsychological Tests; Nitriles; Postmenopause; Statistics, Nonparametric; Surveys and Questionnaires; Tamoxifen; Triazoles | 2010 |
Obesity and hormone therapy in breast cancer: an unfinished puzzle.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Menopause; Nitriles; Obesity; Tamoxifen; Triazoles | 2010 |
Results of the Zometa cost-utility model for the german healthcare system based on the results of the ABCSG-12 study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Costs; Female; Germany; Goserelin; Humans; Imidazoles; Markov Chains; Monte Carlo Method; Multicenter Studies as Topic; National Health Programs; Neoplasms, Multiple Primary; Nitriles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; Zoledronic Acid | 2010 |
The differences in outcome between ATAC and BIG 1-98 suggest efficacy differences between these two nonsteroidal AIs.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Research Design; Tamoxifen; Treatment Outcome; Triazoles | 2010 |
Cognitive changes associated with endocrine therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Cognition; Cognition Disorders; Female; Humans; Letrozole; Memory; Neoplasms, Hormone-Dependent; Nitriles; Prospective Studies; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles; United States; Women's Health | 2010 |
Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of tamoxifen, anastrozole, and letrozole in human plasma and its application to a clinical study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Chromatography, Liquid; Female; Humans; Letrozole; Middle Aged; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Tandem Mass Spectrometry; Triazoles | 2010 |
Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Gonadotropin-Releasing Hormone; Goserelin; Hormones; Humans; Middle Aged; Nitriles; Ovary; Premenopause; Tamoxifen; Triazoles | 2010 |
What is the value of the 21 gene recurrence score in HER2-negative patients?
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Kaplan-Meier Estimate; Nitriles; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; RNA, Neoplasm; Tamoxifen; Triazoles | 2010 |
Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors.
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Estrogen Receptor alpha; Estrogen Receptor beta; Fadrozole; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Nitriles; Phosphorylation; Predictive Value of Tests; Prognosis; Retrospective Studies; Serine; Tamoxifen; Triazoles | 2010 |
10 years of ATAC: one question answered, many others unresolved.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Nitriles; Tamoxifen; Triazoles | 2010 |
[A case of stage IV breast cancer with bone metastases that responded well for long-term to hormonal therapy].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Diphosphonates; Female; Gonadotropin-Releasing Hormone; Humans; Middle Aged; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2010 |
Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Body Mass Index; Breast Neoplasms; Cohort Studies; Female; Hand Strength; Humans; Letrozole; Middle Aged; Musculoskeletal Diseases; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Syndrome; Tamoxifen; Triazoles | 2011 |
Risk of Ipsilateral breast tumor recurrence in patients treated with Tamoxifen or Anastrozole following breast-conserving surgery with or without radiotherapy.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Gene Expression Profiling; Genetic Association Studies; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Oligonucleotide Array Sequence Analysis; Proportional Hazards Models; Proto-Oncogene Proteins c-myc; RNA Interference; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
10-year analysis of the ATAC trial: wrong conclusion?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Predictive algorithms for adjuvant therapy: TransATAC.
Topics: Algorithms; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Ki-67 Antigen; Neoplasm Recurrence, Local; Nitriles; Prognosis; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Ovarian hyperstimulation syndrome in a patient treated with tamoxifen for breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Substitution; Female; Humans; Middle Aged; Nitriles; Ovarian Hyperstimulation Syndrome; Ovariectomy; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer.
Topics: Anastrozole; Androgens; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Gas Chromatography-Mass Spectrometry; Humans; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Steryl-Sulfatase; Tamoxifen; Triazoles | 2011 |
Does trauma or an intercurrent surgical intervention lead to a short-term increase in breast cancer recurrence rates?
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; Surgical Procedures, Operative; Tamoxifen; Triazoles; Wounds and Injuries | 2012 |
Is primary endocrine therapy effective in treating the elderly, unfit patient with breast cancer?
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Female; Humans; Letrozole; Middle Aged; Nitriles; Receptors, Estrogen; Retrospective Studies; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Embracing the complexity of comorbidity.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2011 |
Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Nitriles; Outcome Assessment, Health Care; Postmenopause; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2011 |
The breast cancer chemoprevention debate.
Topics: Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Female; Humans; Models, Statistical; Nitriles; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2011 |
Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease Progression; Female; Follow-Up Studies; Humans; Letrozole; Nitriles; Receptor, ErbB-2; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Ki-67 Antigen; Lapatinib; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoadjuvant Therapy; Nitriles; Predictive Value of Tests; Preoperative Period; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Computer Simulation; Cost-Benefit Analysis; Cytochrome P-450 CYP2D6; Decision Support Techniques; Economics, Pharmaceutical; Female; Genotype; Humans; Markov Chains; Nitriles; Pharmacogenetics; Randomized Controlled Trials as Topic; Research Design; Tamoxifen; Triazoles; United Kingdom | 2011 |
Aromatase inhibitors in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Goserelin; Humans; Neoadjuvant Therapy; Nitriles; Tamoxifen; Triazoles | 2012 |
Deep time: the long and the short of adjuvant endocrine therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2012 |
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cytochrome P-450 CYP2D6; Female; Genotype; Germ-Line Mutation; Glucuronosyltransferase; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Odds Ratio; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Risk Factors; Tamoxifen; Triazoles; United Kingdom | 2012 |
Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Tamoxifen; Triazoles; Weight Gain | 2012 |
Inflammatory osteoarthritis which was precipitated by Arimidex and resolved with tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Female; Humans; Middle Aged; Nitriles; Osteoarthritis; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2010 |
Comparison of the effects of aromatase inhibitors and tamoxifen on radiation-induced lung toxicity: results of an experimental study.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Combined Modality Therapy; Female; Letrozole; Nitriles; Pulmonary Fibrosis; Radiation Injuries, Experimental; Rats; Rats, Wistar; Statistics, Nonparametric; Tamoxifen; Triazoles | 2013 |
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Nitriles; Practice Guidelines as Topic; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Risk Assessment; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Development and validation of a simple and sensitive high performance liquid chromatographic method for the simultaneous determination of anastrozole, bicalutamide, tamoxifen, and their synthetic impurities.
Topics: Analysis of Variance; Anastrozole; Anilides; Calibration; Chromatography, High Pressure Liquid; Limit of Detection; Nitriles; Reproducibility of Results; Tamoxifen; Tosyl Compounds; Triazoles | 2012 |
What is the optimal endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Practice Guidelines as Topic; Receptors, Estrogen; Tamoxifen; Time Factors; Triazoles | 2013 |
Acupuncture for the treatment of hot flashes in patients with breast cancer receiving antiestrogen therapy: a pilot study in Korean women.
Topics: Acupuncture Therapy; Analysis of Variance; Anastrozole; Breast Neoplasms; Estrogen Antagonists; Female; Hot Flashes; Humans; Middle Aged; Nitriles; Prospective Studies; Republic of Korea; Severity of Illness Index; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2013 |
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Topics: Anastrozole; Breast Neoplasms; Female; Gene Expression Profiling; Humans; Neoplasm Recurrence, Local; Nitriles; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Risk; Tamoxifen; Triazoles | 2013 |
Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study.
Topics: Anastrozole; Biomarkers, Tumor; Breast Neoplasms; DNA-Binding Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Ki-67 Antigen; Lymph Nodes; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Transcription Factors; Treatment Outcome; Triazoles | 2013 |
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Differentiation; Cell Growth Processes; Clinical Trials, Phase III as Topic; Female; Gene Expression Profiling; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Signal Transduction; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
Topics: 3-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Member C3; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Biomarkers, Tumor; BRCA1 Protein; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Estrogens; Female; Gene Expression Regulation, Neoplastic; Genetic Markers; Humans; Hydroxyprostaglandin Dehydrogenases; Letrozole; Middle Aged; Nitriles; Receptors, Progesterone; ROC Curve; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Humans; Models, Economic; Models, Structural; Nitriles; Quality-Adjusted Life Years; Survival Analysis; Tamoxifen; Triazoles; Uncertainty | 2014 |
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Prognosis; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies; Risk; Risk Assessment; Tamoxifen; Transcriptome; Treatment Outcome; Triazoles | 2014 |
Women commencing anastrozole, letrozole or tamoxifen for early breast cancer: the impact of comorbidity and demographics on initial choice.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Australia; Breast Neoplasms; Cohort Studies; Comorbidity; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Practice Guidelines as Topic; Premenopause; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles; Tumor Burden | 2014 |
Tumour grade on core biopsy and evidence of axillary involvement on ultrasound predicts response in elderly co-morbid patients treated with primary hormone therapy for oestrogen receptor positive breast carcinoma.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Axilla; Biopsy, Large-Core Needle; Breast Neoplasms; Female; Humans; Letrozole; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Nitriles; Receptors, Estrogen; Retrospective Studies; Tamoxifen; Triazoles | 2015 |
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Tamoxifen; Time Factors; Triazoles | 2014 |
Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Insulin Receptor Substrate Proteins; Ki-67 Antigen; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; PTEN Phosphohydrolase; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Stathmin; Tamoxifen; Triazoles | 2014 |
A hard pill to swallow: a qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Attitude to Health; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Medication Adherence; Middle Aged; Nitriles; Qualitative Research; Quality of Life; Tamoxifen; Triazoles | 2014 |
AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.
Topics: Anastrozole; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; MCF-7 Cells; Nitriles; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Receptors, Androgen; Tamoxifen; Triazoles | 2014 |
Case report: anti-hormonal therapy in the treatment of ductal carcinoma of the parotid gland.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Carcinoma, Ductal; Disease-Free Survival; Female; Humans; Neoplasm Metastasis; Nitriles; Parotid Neoplasms; Tamoxifen; Treatment Outcome; Triazoles | 2014 |
Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogens; Female; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Letrozole; Middle Aged; Musculoskeletal Pain; Nitriles; Prospective Studies; Tamoxifen; Triazoles | 2014 |
Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Australia; Breast Neoplasms; Developed Countries; Drug Utilization Review; England; Female; France; Humans; Internationality; Letrozole; Longitudinal Studies; Netherlands; Nitriles; Scandinavian and Nordic Countries; Tamoxifen; Triazoles | 2015 |
Primary Hormonal Therapy for Elderly Breast Cancer Patients: Single Institution Experience.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Receptors, Estrogen; Retrospective Studies; Spain; Tamoxifen; Treatment Outcome; Triazoles | 2015 |
Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Gonadotropin-Releasing Hormone; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Premenopause; Receptors, Estrogen; Response Evaluation Criteria in Solid Tumors; Tamoxifen; Triazoles | 2015 |
Breast cancer risk reduction therapy: the low-hanging fruit.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast; Breast Neoplasms; Carcinoma in Situ; Female; Humans; Hyperplasia; Nitriles; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2015 |
Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Lymph Nodes; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Tamoxifen; Triazoles | 2015 |
Adjuvant treatments of breast cancer increase the risk of depressive disorders: A population-based study.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Depressive Disorder; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Nitriles; Population Surveillance; Proportional Hazards Models; Retrospective Studies; Risk; Taiwan; Tamoxifen; Trastuzumab; Triazoles | 2015 |
Healthcare professionals' preferences for surgery or primary endocrine therapy to treat older women with operable breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Attitude of Health Personnel; Breast Neoplasms; Female; Geriatrics; Humans; Letrozole; Mastectomy; Nitriles; Oncology Nursing; Patient Preference; Receptors, Estrogen; Surgeons; Surveys and Questionnaires; Tamoxifen; Triazoles; United Kingdom | 2015 |
Evaluation of response to hormone therapy in patients with measurable adult granulosa cell tumors of the ovary.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Female; Goserelin; Granulosa Cell Tumor; Humans; Letrozole; Megestrol Acetate; Middle Aged; Nitriles; Ovarian Neoplasms; Ovariectomy; Radiotherapy, Adjuvant; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Salpingectomy; Tamoxifen; Triazoles | 2015 |
Picking the optimal endocrine adjuvant treatment for pre-menopausal women.
Topics: Age Factors; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Goserelin; Humans; Letrozole; Nitriles; Ovary; Premenopause; Tamoxifen; Triazoles | 2015 |
Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Patient Selection; Prognosis; Tamoxifen; Time Factors; Triazoles | 2015 |
The Effects of Adjuvant Endocrine Treatment on Serum Leptin, Serum Adiponectin and Body Composition in Patients with Breast Cancer: The Izmir Oncology Group (IZOG) Study.
Topics: Adiponectin; Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Composition; Body Mass Index; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Leptin; Letrozole; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2016 |
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Line, Tumor; Cell Self Renewal; Drug Resistance, Neoplasm; Estradiol; Female; Flow Cytometry; Fulvestrant; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; In Vitro Techniques; Interleukin-6; Letrozole; Leuprolide; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Nitriles; Oxidative Phosphorylation; Peptides; Real-Time Polymerase Chain Reaction; Receptor, Notch3; Receptors, Estrogen; Receptors, Notch; Signal Transduction; Tamoxifen; Triazoles | 2016 |
Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Gene Expression Profiling; Health Status Indicators; Humans; Lymph Nodes; Neoplasm Recurrence, Local; Nitriles; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Risk Factors; Tamoxifen; Triazoles | 2016 |
Aromatase inhibitors decrease radiation-induced lung fibrosis: Results of an experimental study.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chemotherapy, Adjuvant; Female; Letrozole; Nitriles; Pulmonary Fibrosis; Radiation Injuries, Experimental; Radiotherapy; Rats; Rats, Wistar; Tamoxifen; Triazoles | 2016 |
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Likelihood Functions; Lymph Nodes; Lymphatic Metastasis; Nitriles; Predictive Value of Tests; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Risk Assessment; Tamoxifen; Triazoles; Tumor Burden | 2016 |
Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biological Assay; Breast Neoplasms; Disease-Free Survival; Female; Homeodomain Proteins; Humans; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Interleukin-17; Receptors, Progesterone; Tamoxifen; Triazoles | 2016 |
Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Breast Neoplasms; Female; Humans; Lasers, Gas; Middle Aged; Nitriles; Retrospective Studies; Surveys and Questionnaires; Tamoxifen; Treatment Outcome; Triazoles; Vagina; Vaginal Diseases; Vulva | 2016 |
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Cytoreduction Surgical Procedures; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Letrozole; Leuprolide; Maintenance Chemotherapy; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Nitriles; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Survival Rate; Tamoxifen; Triazoles; Watchful Waiting; Young Adult | 2017 |
High Initiation of Adjuvant Hormonal Therapy Among Uninsured Stages I-III Breast Cancer Patients Treated in a Safety-Net Healthcare System.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Ethnicity; Female; Humans; Insurance, Health; Medicaid; Medically Uninsured; Neoplasm Staging; Nitriles; Safety-net Providers; Tamoxifen; Treatment Outcome; Triazoles; United States | 2017 |
Melasma treatment: A novel approach using a topical agent that contains an anti-estrogen and a vascular endothelial growth factor inhibitor.
Topics: Administration, Topical; Anastrozole; Androstadienes; Aromatase Inhibitors; Estrogens; Female; Genetic Predisposition to Disease; Humans; Hyperpigmentation; Letrozole; Male; Melanosis; Neovascularization, Pathologic; Nitriles; Pregnancy; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles; Ultraviolet Rays; Vascular Endothelial Growth Factor A | 2017 |
MAMMARY GLAND ADENOCARCINOMA IN A MALE BORNEAN ORANGUTAN (PONGO PYGMAEUS).
Topics: Adenocarcinoma; Anastrozole; Animals; Antineoplastic Agents, Hormonal; Ape Diseases; Male; Mammary Neoplasms, Animal; Neoplasms, Hormone-Dependent; Nitriles; Pongo pygmaeus; Tamoxifen; Triazoles | 2017 |
Avoidance of Negative Results in Adjuvant Endocrine Therapy Trials for Estrogen Receptor-Positive Breast Cancer.
Topics: Anastrozole; Breast Neoplasms; Humans; Letrozole; Negative Results; Postmenopause; Receptors, Estrogen; Tamoxifen | 2017 |
Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Chemotherapy, Adjuvant; Fatty Liver; Female; Humans; Incidence; Letrozole; Lipids; Middle Aged; Nitriles; Propensity Score; Retrospective Studies; Tamoxifen; Triazoles | 2017 |
Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Female; Humans; Letrozole; Medical Overuse; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Ovarian Neoplasms; Retrospective Studies; Survival Analysis; Tamoxifen; Triazoles | 2017 |
Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects.
Topics: Anastrozole; Animals; Bone Morphogenetic Protein Receptors, Type II; Disease Models, Animal; Echocardiography; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Hemodynamics; Humans; Hypertension, Pulmonary; Insulin Resistance; Lung; Mice; Mice, Knockout; Mutation; Nitriles; Signal Transduction; Tamoxifen; Triazoles | 2017 |
Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lymphocyte Count; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Receptors, Estrogen; Risk Factors; Tamoxifen; Triazoles | 2018 |
Risk of ovarian function recovery should be considered when switching from treatment with adjuvant tamoxifen to aromatase inhibitor therapy in women with chemotherapy-induced amenorrhea.
Topics: Amenorrhea; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Recovery of Function; Tamoxifen | 2018 |
The Impact of Perioperative Hormonal Therapy for Breast Cancer on Transverse Rectus Abdominis Myocutaneous Flap Abdominal Complications.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Incisional Hernia; Letrozole; Mammaplasty; Middle Aged; Myocutaneous Flap; Odds Ratio; Rectus Abdominis; Retrospective Studies; Risk Factors; Surgical Wound Infection; Tamoxifen; Treatment Outcome | 2018 |
Adjuvant aromatase inhibition: more options for patients.
Topics: Anastrozole; Androstadienes; Aromatase; Breast Neoplasms; Humans; Letrozole; Tamoxifen | 2018 |
Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Estradiol; Female; Humans; Middle Aged; Ovarian Diseases; Ovary; Prognosis; Randomized Controlled Trials as Topic; Recovery of Function; Tamoxifen | 2017 |
Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cohort Studies; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen | 2018 |
Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.
Topics: Age of Onset; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Postmenopause; Prospective Studies; Tamoxifen; Treatment Outcome | 2018 |
Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Incidence; Medicare; Myocardial Infarction; Prognosis; Risk Factors; SEER Program; Tamoxifen; United States | 2019 |
Development and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology.
Topics: Administration, Oral; Anastrozole; Androstadienes; Androstenes; Anilides; Antineoplastic Agents, Hormonal; Benzamides; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Nitriles; Phenylthiohydantoin; Tamoxifen; Tandem Mass Spectrometry; Tosyl Compounds | 2019 |
Breast cancer cell-induced platelet activation is compounded by tamoxifen and anastrozole in vitro.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Blood Platelets; Breast Neoplasms; Cell Communication; Cell Line, Tumor; Cells, Cultured; Female; Humans; Platelet Activation; Tamoxifen; Thrombosis; Young Adult | 2019 |
Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients.
Topics: Adult; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Australia; Breast Neoplasms; Duration of Therapy; Evidence-Based Medicine; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Medication Adherence; Middle Aged; Neoplasm Staging; Practice Guidelines as Topic; Practice Patterns, Physicians'; Professional Practice Gaps; Receptor, ErbB-2; Retrospective Studies; Tamoxifen; Time Factors; Trastuzumab | 2019 |
Mammary adipose stromal cells derived from obese women reduce sensitivity to the aromatase inhibitor anastrazole in an organotypic breast model.
Topics: Adipocytes; Anastrozole; Aromatase Inhibitors; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Estrogens; Female; Humans; MCF-7 Cells; Obesity; Receptors, Estrogen; Stromal Cells; Tamoxifen | 2019 |
Breast Cancer Chemoprevention: A Practical Guide for the Primary Care Provider.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Decision Making, Shared; Female; Humans; Middle Aged; Physician-Patient Relations; Primary Health Care; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen | 2020 |
Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC study.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Forkhead Box Protein M1; Gene Expression Profiling; Humans; Kruppel-Like Transcription Factors; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Progesterone; Securin; Survival Rate; Tamoxifen | 2020 |
Carryover effects of aromatase inhibitors in prevention.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Humans; Receptors, Estrogen; Tamoxifen | 2020 |
A new immunotherapy schedule in addition to first-line hormone therapy for metastatic breast cancer patients in a state of clinical benefit during hormone therapy.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Female; Humans; Immunotherapy; Letrozole; Male; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Selective Estrogen Receptor Modulators; Survival Analysis; Tamoxifen; Toremifene | 2020 |
[Adjuvant radiotherapy in low-risk breast cancer: long-term results of the ABCSG-8A trial].
Topics: Anastrozole; Breast Neoplasms; Humans; Radiotherapy, Adjuvant; Tamoxifen | 2020 |
The effects of adjuvant hormonotherapy on tear functions in patients with breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Tamoxifen | 2020 |
[Promising long-term results on the use of anastrozole for prevention of breast cancer in postmenopausal high-risk patients].
Topics: Anastrozole; Breast Neoplasms; Humans; Nitriles; Postmenopause; Tamoxifen | 2020 |
Breast Cancer Risk-Reducing Medications.
Topics: Adult; Age Factors; Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2020 |
Molecular Drivers of Onco
Topics: Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Predictive Value of Tests; Randomized Controlled Trials as Topic; Risk Assessment; RNA, Neoplasm; Tamoxifen | 2021 |
Urinary Incontinence and Overactive Bladder Symptoms in Women with Breast Cancer Being Treated with Oral Hormone Therapy.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cross-Sectional Studies; Female; Humans; Interviews as Topic; Medication Adherence; Middle Aged; Portugal; Tamoxifen; Urinary Bladder, Overactive; Urinary Incontinence | 2020 |
Switching of Hormone Therapies in Breast Cancer Women.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Sectional Studies; Disease Progression; Female; Humans; Medical Records; Neoplasm Recurrence, Local; Patient Participation; Retrospective Studies; Tamoxifen; Young Adult | 2021 |
Palliative treatment of endometrial cancer: what is the role of anastrozole in elderly women?
Topics: Aged; Aged, 80 and over; Anastrozole; Endometrial Neoplasms; Female; Humans; Nitriles; Palliative Care; Pilot Projects; Quality of Life; Tamoxifen; Triazoles | 2021 |
Dual treatment of acromegaly and hormone-receptor-positive breast cancer with tamoxifen: a case report.
Topics: Acromegaly; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Nitriles; Tamoxifen | 2021 |
The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Genetic Testing; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Tamoxifen | 2021 |
RE: Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Perimenopause; Tamoxifen | 2022 |
Design and synthesis of marine sesterterpene analogues as novel estrogen receptor α degraders for breast cancer treatment.
Topics: Anastrozole; Antineoplastic Agents; Apoptosis; Biological Products; Breast Neoplasms; Cell Proliferation; Down-Regulation; Estrogen Receptor alpha; Humans; Letrozole; MCF-7 Cells; Molecular Docking Simulation; Protein Binding; Proteolysis; Raloxifene Hydrochloride; Reactive Oxygen Species; Sesterterpenes; Signal Transduction; Structure-Activity Relationship; Tamoxifen | 2022 |
Health-related quality of life among elderly breast cancer patients treated with adjuvant endocrine therapy: a U.S Medicare population-based study.
Topics: Aged; Anastrozole; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Sectional Studies; Female; Humans; Letrozole; Male; Medicare; Quality of Life; Retrospective Studies; Tamoxifen; United States | 2022 |
Topics: Anastrozole; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Carica; Catechin; Chlorogenic Acid; Cyclophosphamide; Estrogen Receptor Modulators; Estrogens; Female; Humans; Letrozole; Ligands; Molecular Docking Simulation; Paclitaxel; Quercetin; Tamoxifen; Trastuzumab | 2022 |
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac Glycosides; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Letrozole; MCF-7 Cells; Ouabain; Precision Medicine; Sodium-Potassium-Exchanging ATPase; Tamoxifen | 2022 |
Adherence to Adjuvant Endocrine Therapy and Survival Among Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Medicare; Nitriles; Tamoxifen; United States | 2023 |
Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare.
Topics: Aged; Anastrozole; Cost Savings; Drug Costs; Drugs, Generic; Humans; Imatinib Mesylate; Letrozole; Medicare Part D; Prescription Drugs; Tamoxifen; United States | 2023 |
[De-escalation in aromatase inhibitors prescription for menopausal women with positive hormonal receptors breast cancer].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Menopause; Tamoxifen | 2023 |
Breast Tumor Cells Evade the Cytotoxic Action of Anastrozole, Aspirin, and Clopidogrel Cocktail.
Topics: Anastrozole; Animals; Antineoplastic Agents; Aspirin; Breast Neoplasms; Clopidogrel; Female; Humans; Mammary Neoplasms, Animal; Nitriles; Tamoxifen; Triazoles | 2023 |
Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial.
Topics: Anastrozole; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Patient Reported Outcome Measures; Tamoxifen | 2023 |
Anastrozole: Repurposed drug could prevent thousands of breast cancer cases.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Nitriles; Tamoxifen | 2023 |